☰

Ralf Gold - Publications

Affiliations: 
St. Josefs Hopital, Denver, CO, United States 
Tree Info Grants Similar researchers PubMed Report error

302 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2020 Gold R, Montalban X, Haghikia A. Multiple sclerosis and nutrition: back to the future? Therapeutic Advances in Neurological Disorders. 13: 1756286420936165. PMID 32863887 DOI: 10.1177/1756286420936165  0.34
2020 Grüter T, Motte J, Fisse AL, Bulut Y, Köse N, Athanasopoulos D, Otto S, Yoon MS, Schneider-Gold C, Gold R, Pitarokoili K. Pathological spontaneous activity as a prognostic marker in chronic inflammatory demyelinating polyneuropathy. European Journal of Neurology. PMID 32794258 DOI: 10.1111/Ene.14476  0.316
2020 Wurm H, Attfield K, Iversen AK, Gold R, Fugger L, Haghikia A. Recovery from COVID-19 in a B-cell-depleted multiple sclerosis patient. Multiple Sclerosis (Houndmills, Basingstoke, England). 1352458520943791. PMID 32762494 DOI: 10.1177/1352458520943791  0.349
2020 Zella MAS, Bartig D, Herrmann L, Respondek G, Höglinger G, Gold R, Woitalla D, Krogias C, Tönges L. Hospitalization Rates and Comorbidities in Patients with Progressive Supranuclear Palsy in Germany from 2010 to 2017. Journal of Clinical Medicine. 9. PMID 32751888 DOI: 10.3390/Jcm9082454  0.31
2020 Gasperi C, Andlauer TFM, Keating A, Knier B, Klein A, Pernpeintner V, Lichtner P, Gold R, Zipp F, Then Bergh F, Stangel M, Tumani H, Wildemann B, Wiendl H, Bayas A, et al. Genetic determinants of the humoral immune response in MS. Neurology(R) Neuroimmunology & Neuroinflammation. 7. PMID 32675288 DOI: 10.1212/Nxi.0000000000000827  0.336
2020 Waldera-Lupa DM, Poschmann G, Kirchgaessler N, Etemad-Parishanzadeh O, Baberg F, Brocksieper M, Seidel S, Kowalski T, Brunn A, Haghikia A, Gold R, Stefanski A, Deckert M, Schlegel U, Stühler K. A Multiplex Assay for the Stratification of Patients with Primary Central Nervous System Lymphoma Using Targeted Mass Spectrometry. Cancers. 12. PMID 32610669 DOI: 10.3390/Cancers12071732  0.304
2020 Bittner S, Steffen F, Uphaus T, Muthuraman M, Fleischer V, Salmen A, Luessi F, Berthele A, Klotz L, Meuth SG, Bayas A, Paul F, Hartung HP, Linker R, Heesen C, ... ... Gold R, et al. Clinical implications of serum neurofilament in newly diagnosed MS patients: A longitudinal multicentre cohort study. Ebiomedicine. 56: 102807. PMID 32460167 DOI: 10.1016/J.Ebiom.2020.102807  0.354
2020 Gold R, Arnold DL, Bar-Or A, Fox RJ, Kappos L, Chen C, Parks B, Miller C. Safety and efficacy of delayed-release dimethyl fumarate in patients with relapsing-remitting multiple sclerosis: 9 years' follow-up of DEFINE, CONFIRM, and ENDORSE. Therapeutic Advances in Neurological Disorders. 13: 1756286420915005. PMID 32426039 DOI: 10.1177/1756286420915005  0.309
2020 Abrahamyan S, Eberspächer B, Hoshi MM, Aly L, Luessi F, Groppa S, Klotz L, Meuth SG, Schroeder C, Grüter T, Tackenberg B, Paul F, Then-Bergh F, Kümpfel T, Weber F, ... ... Gold R, et al. Complete Epstein-Barr virus seropositivity in a large cohort of patients with early multiple sclerosis. Journal of Neurology, Neurosurgery, and Psychiatry. PMID 32371533 DOI: 10.1136/Jnnp-2020-322941  0.338
2020 Engel S, Graetz C, Salmen A, Muthuraman M, Toenges G, Ambrosius B, Bayas A, Berthele A, Heesen C, Klotz L, Kümpfel T, Linker RA, Meuth SG, Paul F, Stangel M, ... ... Gold R, et al. Is ε4 associated with cognitive performance in early MS? Neurology(R) Neuroimmunology & Neuroinflammation. 7. PMID 32358224 DOI: 10.1212/Nxi.0000000000000728  0.314
2020 Duscha A, Gisevius B, Hirschberg S, Yissachar N, Stangl GI, Eilers E, Bader V, Haase S, Kaisler J, David C, Schneider R, Troisi R, Zent D, Hegelmaier T, Dokalis N, ... ... Gold R, et al. Propionic Acid Shapes the Multiple Sclerosis Disease Course by an Immunomodulatory Mechanism. Cell. PMID 32160527 DOI: 10.1016/J.Cell.2020.02.035  0.371
2020 Faissner S, Schwake C, Gotzmann M, Mügge A, Schmidt S, Gold R. Endocarditis following ocrelizumab in relapsing-remitting MS. Neurology(R) Neuroimmunology & Neuroinflammation. 7. PMID 32014890 DOI: 10.1212/Nxi.0000000000000680  0.352
2020 Kruczek P, Bellenberg B, Lutz T, Schneider R, Ahlborn C, Gold R, Köster O, Lukas C. Developmental Venous Anomalies are More Common in Patients with Multiple Sclerosis and Clinically Isolated Syndrome : Coincidence or Relevant? Clinical Neuroradiology. PMID 31897504 DOI: 10.1007/S00062-019-00869-Y  0.347
2019 Haupeltshofer S, Leichsenring T, Berg S, Pedreiturria X, Joachim SC, Tischoff I, Otte JM, Bopp T, Fantini MC, Esser C, Willbold D, Gold R, Faissner S, Kleiter I. Smad7 in intestinal CD4 T cells determines autoimmunity in a spontaneous model of multiple sclerosis. Proceedings of the National Academy of Sciences of the United States of America. PMID 31796589 DOI: 10.1073/Pnas.1905955116  0.315
2019 Faissner S, Gold R. [New therapeutic approaches in progressive multiple sclerosis]. Fortschritte Der Neurologie-Psychiatrie. 87: 653-671. PMID 31783427 DOI: 10.1055/A-0880-0073  0.384
2019 Schneider R, Genç E, Ahlborn C, Gold R, Lukas C, Bellenberg B. Temporal Dynamics of Diffusion Metrics in Early Multiple Sclerosis and Clinically Isolated Syndrome: A 2-Year Follow-Up Tract-Based Spatial Statistics Study. Frontiers in Neurology. 10: 1165. PMID 31749760 DOI: 10.3389/Fneur.2019.01165  0.319
2019 Grüter T, Ott A, Meyer W, Jarius S, Kinner M, Motte J, Pitarokoili K, Gold R, Komorowski L, Ayzenberg I. Effects of IVIg treatment on autoantibody testing in neurological patients: marked reduction in sensitivity but reliable specificity. Journal of Neurology. PMID 31728710 DOI: 10.1007/S00415-019-09614-4  0.345
2019 Faissner S, Gold R. Progressive multiple sclerosis: latest therapeutic developments and future directions. Therapeutic Advances in Neurological Disorders. 12: 1756286419878323. PMID 31598138 DOI: 10.1177/1756286419878323  0.402
2019 Motte J, Kneiphof J, Straßburger-Krogias K, Pitarokoili K, Fisse AL, Kappos L, Gold R. Hereditary defect of cobalamin metabolism with adolescence onset resembling multiple sclerosis: 41-year follow up in two cases. Therapeutic Advances in Neurological Disorders. 12: 1756286419872115. PMID 31489032 DOI: 10.1177/1756286419872115  0.348
2019 Ayzenberg I, Ellrichmann G, Schroeder C, Tönges L, Klasing A, Pappa V, Brück W, Gold R. Brainstem Encephalitis With Low-Titer Acetylcholine Receptor Antibodies Mimicking Myasthenia Gravis. Frontiers in Neurology. 10: 829. PMID 31428040 DOI: 10.3389/Fneur.2019.00829  0.315
2019 Faissner S, Plemel JR, Gold R, Yong VW. Progressive multiple sclerosis: from pathophysiology to therapeutic strategies. Nature Reviews. Drug Discovery. PMID 31399729 DOI: 10.1038/S41573-019-0035-2  0.371
2019 Sinnecker T, Hadisurya J, Schneider-Hohendorf T, Schwab N, Wrede K, Gembruch O, Gold R, Hellwig K, Pilgram-Pastor S, Adams O, Albrecht P, Hartung HP, Aktas O, Kraemer M. Extensive immune reconstitution inflammatory syndrome in Fingolimod-associated PML: a case report with 7 Tesla MRI data. Bmc Neurology. 19: 190. PMID 31399069 DOI: 10.1186/S12883-019-1407-2  0.306
2019 Metzdorf J, Hobloss Z, Schlevogt S, Ayzenberg I, Stahlke S, Pedreiturria X, Haupeltshofer S, Gold R, Tönges L, Kleiter I. Fingolimod for Irradiation-Induced Neurodegeneration. Frontiers in Neuroscience. 13: 699. PMID 31354410 DOI: 10.3389/Fnins.2019.00699  0.313
2019 Bittner S, Engel S, Lange C, Weber MS, Haghikia A, Luessi F, Korn T, Klotz L, Bayas A, Paul F, Heesen C, Stangel M, Wildemann B, Bergh FT, Tackenberg B, ... ... Gold R, et al. [Diagnostics and treatment of tuberculosis under immunotherapy for multiple sclerosis : Current status and recommendations in Germany]. Der Nervenarzt. PMID 31297574 DOI: 10.1007/S00115-019-0760-0  0.32
2019 Richter D, Bartig D, Jost W, Jörges C, Stumpe B, Gold R, Krogias C, Tönges L. Dynamics of device-based treatments for Parkinson's disease in Germany from 2010 to 2017: application of continuous subcutaneous apomorphine, levodopa-carbidopa intestinal gel, and deep brain stimulation. Journal of Neural Transmission (Vienna, Austria : 1996). PMID 31222604 DOI: 10.1007/S00702-019-02034-8  0.302
2019 Gasperi C, Salmen A, Antony G, Bayas A, Heesen C, Kümpfel T, Linker RA, Paul F, Stangel M, Tackenberg B, Bergh FT, Warnke C, Weber F, Wiendl H, Wildemann B, ... ... Gold R, et al. Association of Intrathecal Immunoglobulin G Synthesis With Disability Worsening in Multiple Sclerosis. Jama Neurology. PMID 31034002 DOI: 10.1001/Jamaneurol.2019.0905  0.338
2019 Hoepner R, Bagnoud M, Pistor M, Salmen A, Briner M, Synn H, Schrewe L, Guse K, Ahmadi F, Demir S, Laverick L, Gresle M, Worley P, Reichardt HM, Butzkueven H, ... Gold R, et al. Vitamin D increases glucocorticoid efficacy via inhibition of mTORC1 in experimental models of multiple sclerosis. Acta Neuropathologica. PMID 31030237 DOI: 10.1007/S00401-019-02018-8  0.324
2019 Coyle PK, Khatri B, Edwards KR, Meca-Lallana JE, Cavalier S, Rufi P, Benamor M, Poole EM, Robinson M, Gold R. Teriflunomide real-world evidence: Global differences in the phase 4 Teri-PRO study. Multiple Sclerosis and Related Disorders. 31: 157-164. PMID 31005729 DOI: 10.1016/J.Msard.2019.03.022  0.315
2019 Krogias C, Christou I, Tsivgoulis G, Koutroulou I, Schroeder C, Lantinioti C, Richter D, Karapanayiotides T, Haghikia A, Gold R, Voumvourakis K. Functional Neurosonology Reveals Impaired Cerebrovascular Reactivity in Multiple Sclerosis. Journal of Neuroimaging : Official Journal of the American Society of Neuroimaging. PMID 30990241 DOI: 10.1111/Jon.12617  0.35
2019 Mehta D, Miller C, Arnold DL, Bame E, Bar-Or A, Gold R, Hanna J, Kappos L, Liu S, Matta A, Phillips JT, Robertson D, von Hehn CA, Campbell J, Spach K, et al. Effect of dimethyl fumarate on lymphocytes in RRMS: Implications for clinical practice. Neurology. PMID 30918100 DOI: 10.1212/Wnl.0000000000007262  0.331
2019 Ellrichmann G, Blusch A, Fatoba O, Brunner J, Reick C, Hayardeny L, Hayden M, Sehr D, Winklhofer KF, Saft C, Gold R. Author Correction: Laquinimod treatment in the R6/2 mouse model. Scientific Reports. 9: 4960. PMID 30874566 DOI: 10.1038/S41598-018-37926-4  0.689
2019 Vohl K, Duscha A, Gisevius B, Kaisler J, Gold R, Haghikia A. Predictors for Therapy Response to Intrathecal Corticosteroid Therapy in Multiple Sclerosis. Frontiers in Neurology. 10: 132. PMID 30853935 DOI: 10.3389/Fneur.2019.00132  0.34
2019 Dalla Costa G, Martinelli V, Moiola L, Sangalli F, Colombo B, Finardi A, Cinque P, Kolb EM, Haghikia A, Gold R, Furlan R, Comi G. Serum neurofilaments increase at PML onset in natalizumab-treated MS patients. Annals of Neurology. PMID 30761586 DOI: 10.1002/Ana.25437  0.377
2019 Masuda T, Sankowski R, Staszewski O, Böttcher C, Amann L, Scheiwe C, Nessler S, Kunz P, van Loo G, Coenen VA, Reinacher PC, Michel A, Sure U, Gold R, Priller J, et al. Spatial and temporal heterogeneity of mouse and human microglia at single-cell resolution. Nature. PMID 30760929 DOI: 10.1038/S41586-019-0924-X  0.342
2019 Gold R, Giovannoni G, Phillips T, Bar-Or A, Fox RJ, Chen C, Miller C. Delayed-release Dimethyl Fumarate demonstrates sustained efficacy over nine years in newly diagnosed patients with relapsing-remitting multiple Sclerosis Revue Neurologique. 175. DOI: 10.1016/J.Neurol.2019.01.263  0.307
2018 Demir S, Pitarokoili K, Linker R, Gold R. Immune cell derived BDNF does not mediate neuroprotection of the murine anti-CD52 antibody in a chronic autoimmune mouse model. Journal of Neuroimmunology. 328: 78-85. PMID 30623801 DOI: 10.1016/J.Jneuroim.2018.12.010  0.328
2018 Zella SMA, Metzdorf J, Ciftci E, Ostendorf F, Muhlack S, Gold R, Tönges L. Emerging Immunotherapies for Parkinson Disease. Neurology and Therapy. PMID 30539376 DOI: 10.1007/S40120-018-0122-Z  0.315
2018 Johnen A, Bürkner PC, Landmeyer NC, Ambrosius B, Calabrese P, Motte J, Hessler N, Antony G, König IR, Klotz L, Hoshi MM, Aly L, Groppa S, Luessi F, Paul F, ... ... Gold R, et al. Can we predict cognitive decline after initial diagnosis of multiple sclerosis? Results from the German National early MS cohort (KKNMS). Journal of Neurology. PMID 30515631 DOI: 10.1007/S00415-018-9142-Y  0.316
2018 Ellrichmann G, Bolz J, Peschke M, Duscha A, Hellwig K, Lee DH, Linker RA, Gold R, Haghikia A. Peripheral CD19 B-cell counts and infusion intervals as a surrogate for long-term B-cell depleting therapy in multiple sclerosis and neuromyelitis optica/neuromyelitis optica spectrum disorders. Journal of Neurology. PMID 30377816 DOI: 10.1007/S00415-018-9092-4  0.363
2018 Coyle PK, Khatri B, Edwards KR, Meca-Lallana JE, Cavalier S, Rufi P, Benamor M, Thangavelu K, Robinson M, Gold R. Patient-reported outcomes in patients with relapsing forms of MS switching to teriflunomide from other disease-modifying therapies: Results from the global Phase 4 Teri-PRO study in routine clinical practice. Multiple Sclerosis and Related Disorders. 26: 211-218. PMID 30273841 DOI: 10.1016/J.Msard.2018.09.017  0.365
2018 Schroeder C, Back C, Koc Ü, Strassburger-Krogias K, Reinacher-Schick A, Gold R, Haghikia A. Breakthrough treatment with bortezomib for a patient with anti-NMDAR encephalitis. Clinical Neurology and Neurosurgery. 172: 24-26. PMID 29960102 DOI: 10.1016/J.Clineuro.2018.06.005  0.33
2018 Motte J, Kneiphof J, Straßburger-Krogias K, Klasing A, Adams O, Haghikia A, Gold R. Detection of JC virus archetype in cerebrospinal fluid in a MS patient with dimethylfumarate treatment without lymphopenia or signs of PML. Journal of Neurology. PMID 29948248 DOI: 10.1007/S00415-018-8931-7  0.326
2018 Hammer A, Waschbisch A, Kuhbandner K, Bayas A, Lee DH, Duscha A, Haghikia A, Gold R, Linker RA. The NRF2 pathway as potential biomarker for dimethyl fumarate treatment in multiple sclerosis. Annals of Clinical and Translational Neurology. 5: 668-676. PMID 29928650 DOI: 10.1002/Acn3.553  0.391
2018 Wilmes AT, Reinehr S, Kühn S, Pedreiturria X, Petrikowski L, Faissner S, Ayzenberg I, Stute G, Gold R, Dick HB, Kleiter I, Joachim SC. Laquinimod protects the optic nerve and retina in an experimental autoimmune encephalomyelitis model. Journal of Neuroinflammation. 15: 183. PMID 29903027 DOI: 10.1186/S12974-018-1208-3  0.346
2018 Gold R, Schlegel E, Elias-Hamp B, Albert C, Schmidt S, Tackenberg B, Xiao J, Schaak T, Salmen HC. Incidence and mitigation of gastrointestinal events in patients with relapsing-remitting multiple sclerosis receiving delayed-release dimethyl fumarate: a German phase IV study (TOLERATE). Therapeutic Advances in Neurological Disorders. 11: 1756286418768775. PMID 29707040 DOI: 10.1177/1756286418768775  0.332
2018 Huhn K, Bayas A, Doerck S, Frank B, Gerbershagen K, Hellwig K, Kallmann B, Kleinschnitz C, Kleiter I, Lee DH, Limmroth V, Mäurer M, Meuth S, Rieckmann P, Ruck T, ... Gold R, et al. Alemtuzumab as rescue therapy in a cohort of 50 relapsing-remitting MS patients with breakthrough disease on fingolimod: a multi-center observational study. Journal of Neurology. PMID 29696498 DOI: 10.1007/S00415-018-8871-2  0.384
2018 Motte J, Ambrosius B, Grüter T, Bachir H, Sgodzai M, Pedreiturria X, Pitarokoili K, Gold R. Capsaicin-enriched diet ameliorates autoimmune neuritis in rats. Journal of Neuroinflammation. 15: 122. PMID 29690884 DOI: 10.1186/S12974-018-1165-X  0.302
2018 Faissner S, Gold R. Efficacy and Safety of the Newer Multiple Sclerosis Drugs Approved Since 2010. Cns Drugs. PMID 29600441 DOI: 10.1007/S40263-018-0488-6  0.356
2018 Graetz C, Gröger A, Luessi F, Salmen A, Zöller D, Schultz J, Siller N, Fleischer V, Bellenberg B, Berthele A, Biberacher V, Havla J, Hecker M, Hohlfeld R, Infante-Duarte C, ... ... Gold R, et al. Association of smoking but not HLA-DRB1*15:01, APOE or body mass index with brain atrophy in early multiple sclerosis. Multiple Sclerosis (Houndmills, Basingstoke, England). 1352458518763541. PMID 29532745 DOI: 10.1177/1352458518763541  0.338
2018 Kita M, Fox RJ, Gold R, Giovannoni G, Phillips JT, Sarda SP, Kong J, Viglietta V, Sheikh SI, Okwuokenye M, Kappos L. Corrigendum to 'Effects of Delayed-Release Dimethyl Fumarate (DMF) on Health-Related Quality of Life in Patients With Relapsing-Remitting Multiple Sclerosis: An Integrated Analysis of the Phase 3 DEFINE and CONFIRM Studies: [Clinical Therapeutics 36 (2014) 1958-1971]. Clinical Therapeutics. PMID 29523369 DOI: 10.1016/J.Clinthera.2018.02.005  0.302
2018 von Bismarck O, Dankowski T, Ambrosius B, Hessler N, Antony G, Ziegler A, Hoshi MM, Aly L, Luessi F, Groppa S, Klotz L, Meuth SG, Tackenberg B, Stoppe M, Then Bergh F, ... ... Gold R, et al. Treatment choices and neuropsychological symptoms of a large cohort of early MS. Neurology(R) Neuroimmunology & Neuroinflammation. 5: e446. PMID 29511705 DOI: 10.1212/Nxi.0000000000000446  0.345
2018 Faissner S, Gold R. Oral Therapies for Multiple Sclerosis. Cold Spring Harbor Perspectives in Medicine. PMID 29500302 DOI: 10.1101/Cshperspect.A032011  0.32
2018 Faissner S, Gold R. Clinical commentary on 'Severe hypertriglyceridemia associated with teriflunomide in a patient with multiple sclerosis'. Multiple Sclerosis (Houndmills, Basingstoke, England). 1352458518761188. PMID 29473795 DOI: 10.1177/1352458518761188  0.343
2018 Montalban X, Gold R, Thompson AJ, Otero-Romero S, Amato MP, Chandraratna D, Clanet M, Comi G, Derfuss T, Fazekas F, Hartung HP, Havrdova E, Hemmer B, Kappos L, Liblau R, et al. ECTRIMS/EAN Guideline on the pharmacological treatment of people with multiple sclerosis. Multiple Sclerosis (Houndmills, Basingstoke, England). 1352458517751049. PMID 29353550 DOI: 10.1177/1352458517751049  0.356
2018 Montalban X, Gold R, Thompson AJ, Otero-Romero S, Amato MP, Chandraratna D, Clanet M, Comi G, Derfuss T, Fazekas F, Hartung HP, Havrdova E, Hemmer B, Kappos L, Liblau R, et al. ECTRIMS/EAN guideline on the pharmacological treatment of people with multiple sclerosis. European Journal of Neurology. PMID 29352526 DOI: 10.1111/Ene.13536  0.352
2018 Fatoba O, Kloster E, Reick C, Saft C, Gold R, Epplen JT, Arning L, Ellrichmann G. Activation of NPY-Y2 receptors ameliorates disease pathology in the R6/2 mouse and PC12 cell models of Huntington's disease. Experimental Neurology. PMID 29309751 DOI: 10.1016/J.Expneurol.2018.01.001  0.722
2018 Haase S, Haghikia A, Gold R, Linker RA. Dietary fatty acids and susceptibility to multiple sclerosis. Multiple Sclerosis (Houndmills, Basingstoke, England). 24: 12-16. PMID 29307296 DOI: 10.1177/1352458517737372  0.375
2018 Grüter T, Metz I, Gahlen A, Kneiphof J, Stork L, Brück W, Gold R, Kleiter I. Mitoxantrone treatment in a patient with multiple sclerosis and pattern III lesions Clinical and Experimental Neuroimmunology. 9: 169-172. DOI: 10.1111/Cen3.12466  0.311
2018 Gold R. Erstmalig europäische Leitlinien zur MS-Therapie Aktuelle Neurologie. 45: 5-6. DOI: 10.1055/S-0043-124577  0.33
2018 Thiel S, Leypoldt F, Röpke L, Wandinger K, Kümpfel T, Aktas O, von Bismarck O, Salmen A, Ambrosius B, Ellrichmann G, Antony G, Dankowski T, Ziegler A, Stahmann A, Meyer C, ... ... Gold R, et al. Neuroimmunologische Register in Deutschland Aktuelle Neurologie. 45: 7-23. DOI: 10.1055/S-0043-108909  0.304
2017 Pitarokoili K, Ambrosius B, Gold R. Lewis Rat Model of Experimental Autoimmune Encephalomyelitis. Current Protocols in Neuroscience. 81: 9.61.1-9.61.20. PMID 29058769 DOI: 10.1002/Cpns.36  0.339
2017 Rose JW, Giovannoni G, Wiendl H, Gold R, Havrdová E, Kappos L, Selmaj KW, Zhao J, Riester K, Tsao LC, Greenberg SJ. Consistent efficacy of daclizumab beta across patient demographic and disease activity subgroups in patients with relapsing-remitting multiple sclerosis. Multiple Sclerosis and Related Disorders. 17: 32-40. PMID 29055471 DOI: 10.1016/J.Msard.2017.06.006  0.315
2017 Coyle PK, Khatri B, Edwards KR, Meca-Lallana JE, Cavalier S, Rufi P, Benamor M, Brette S, Robinson M, Gold R. Patient-reported outcomes in relapsing forms of MS: Real-world, global treatment experience with teriflunomide from the Teri-PRO study. Multiple Sclerosis and Related Disorders. 17: 107-115. PMID 29055438 DOI: 10.1016/J.Msard.2017.07.006  0.354
2017 Schneider R, Bellenberg B, Hoepner R, Ellrichmann G, Gold R, Lukas C. Insight into Metabolic (1)H-MRS Changes in Natalizumab Induced Progressive Multifocal Leukoencephalopathy Brain Lesions. Frontiers in Neurology. 8: 454. PMID 28928709 DOI: 10.3389/Fneur.2017.00454  0.349
2017 Plavina T, Muralidharan KK, Kuesters G, Mikol D, Evans K, Subramanyam M, Nestorov I, Chen Y, Dong Q, Ho PR, Amarante D, Adams A, De Sèze J, Fox R, Gold R, et al. Reversibility of the effects of natalizumab on peripheral immune cell dynamics in MS patients. Neurology. PMID 28916537 DOI: 10.1212/Wnl.0000000000004485  0.388
2017 Hammer A, Schliep A, Jörg S, Haghikia A, Gold R, Kleinewietfeld M, Müller DN, Linker RA. Impact of combined sodium chloride and saturated long-chain fatty acid challenge on the differentiation of T helper cells in neuroinflammation. Journal of Neuroinflammation. 14: 184. PMID 28899400 DOI: 10.1186/S12974-017-0954-Y  0.307
2017 Faissner S, Mahjoub Y, Mishra M, Haupeltshofer S, Hahn JN, Gold R, Koch M, Metz LM, Ben-Hur T, Yong VW. Unexpected additive effects of minocycline and hydroxychloroquine in models of multiple sclerosis: Prospective combination treatment for progressive disease? Multiple Sclerosis (Houndmills, Basingstoke, England). 1352458517728811. PMID 28857721 DOI: 10.1177/1352458517728811  0.38
2017 Pitarokoili K, Yoon MS, Kröger I, Reinacher-Schick A, Gold R, Schneider-Gold C. Severe refractory CIDP: a case series of 10 patients treated with bortezomib. Journal of Neurology. PMID 28836002 DOI: 10.1007/S00415-017-8599-4  0.338
2017 Fox RJ, Gold R, Phillips JT, Okwuokenye M, Zhang A, Marantz JL. Efficacy and Tolerability of Delayed-release Dimethyl Fumarate in Black, Hispanic, and Asian Patients with Relapsing-Remitting Multiple Sclerosis: Post Hoc Integrated Analysis of DEFINE and CONFIRM. Neurology and Therapy. PMID 28770420 DOI: 10.1007/S40120-017-0077-5  0.379
2017 Fernández Ó, Giovannoni G, Fox RJ, Gold R, Phillips JT, Potts J, Okwuokenye M, Marantz JL. Efficacy and Safety of Delayed-release Dimethyl Fumarate for Relapsing-Remitting Multiple Sclerosis in Prior Interferon Users: An Integrated Analysis of DEFINE and CONFIRM. Clinical Therapeutics. PMID 28751099 DOI: 10.1016/J.Clinthera.2017.06.012  0.358
2017 Ellrichmann G, Blusch A, Fatoba O, Brunner J, Hayardeny L, Hayden M, Sehr D, Winklhofer KF, Saft C, Gold R. Laquinimod treatment in the R6/2 mouse model. Scientific Reports. 7: 4947. PMID 28694434 DOI: 10.1038/S41598-017-04990-1  0.731
2017 Gahlen A, Trampe AK, Haupeltshofer S, Ringelstein M, Aktas O, Berthele A, Wildemann B, Gold R, Jarius S, Kleiter I. Aquaporin-4 antibodies in patients treated with natalizumab for suspected MS. Neurology(R) Neuroimmunology & Neuroinflammation. 4: e363. PMID 28642888 DOI: 10.1212/Nxi.0000000000000363  0.381
2017 Massa MG, David C, Jörg S, Berg J, Gisevius B, Hirschberg S, Linker RA, Gold R, Haghikia A. Testosterone Differentially Affects T Cells and Neurons in Murine and Human Models of Neuroinflammation and Neurodegeneration. The American Journal of Pathology. 187: 1613-1622. PMID 28634006 DOI: 10.1016/J.Ajpath.2017.03.006  0.384
2017 Pitarokoili K, Kohle F, Motte J, Fatoba O, Pedreiturria X, Gold R, Yoon MS. Anti-inflammatory and immunomodulatory potential of human immunoglobulin applied intrathecally in Lewis rat experimental autoimmune neuritis. Journal of Neuroimmunology. 309: 58-67. PMID 28601289 DOI: 10.1016/J.Jneuroim.2017.05.008  0.722
2017 Hagström IT, Schneider R, Bellenberg B, Salmen A, Weiler F, Köster O, Gold R, Lukas C. Relevance of early cervical cord volume loss in the disease evolution of clinically isolated syndrome and early multiple sclerosis: a 2-year follow-up study. Journal of Neurology. PMID 28600596 DOI: 10.1007/S00415-017-8537-5  0.304
2017 Ambrosius B, Pitarokoili K, Schrewe L, Pedreiturria X, Motte J, Gold R. Fingolimod attenuates experimental autoimmune neuritis and contributes to Schwann cell-mediated axonal protection. Journal of Neuroinflammation. 14: 92. PMID 28446186 DOI: 10.1186/S12974-017-0864-Z  0.352
2017 Schneider R, Bellenberg B, Hoepner R, Kolb EM, Ellrichmann G, Haghikia A, Gold R, Lukas C. Metabolic profiles by 1H-magnetic resonance spectroscopy in natalizumab-associated post-PML lesions of multiple sclerosis patients who survived progressive multifocal leukoencephalopathy (PML). Plos One. 12: e0176415. PMID 28445498 DOI: 10.1371/Journal.Pone.0176415  0.337
2017 Ellrichmann G, Gold R, Ayzenberg I, Yoon MS, Schneider-Gold C. Two years' long-term follow up in chronic inflammatory demyelinating polyradiculoneuropathy: efficacy of intravenous immunoglobulin treatment. Therapeutic Advances in Neurological Disorders. 10: 91-101. PMID 28382108 DOI: 10.1177/1756285616679369  0.313
2017 Thone J, Thiel S, Gold R, Hellwig K. Treatment of multiple sclerosis during pregnancy - safety considerations. Expert Opinion On Drug Safety. PMID 28333552 DOI: 10.1080/14740338.2017.1311321  0.346
2017 Pitarokoili K, Hellwig K, Lukas C, Gold R. Successful pregnancy after natalizumab-associated progressive multifocal leukoencephalopathy in a patient with multiple sclerosis. Multiple Sclerosis (Houndmills, Basingstoke, England). 23: 483-486. PMID 28260421 DOI: 10.1177/1352458516678475  0.355
2017 Wilhelms W, Bellenberg B, Köster O, Weiler F, Hoffmann R, Gold R, Saft C, Lukas C. Progressive spinal cord atrophy in manifest and premanifest Huntington's disease. Journal of Neurology, Neurosurgery, and Psychiatry. PMID 28209652 DOI: 10.1136/Jnnp-2016-315000  0.317
2017 Gopal S, Mikulskis A, Gold R, Fox RJ, Dawson KT, Amaravadi L. Evidence of activation of the Nrf2 pathway in multiple sclerosis patients treated with delayed-release dimethyl fumarate in the Phase 3 DEFINE and CONFIRM studies. Multiple Sclerosis (Houndmills, Basingstoke, England). 1352458517690617. PMID 28156185 DOI: 10.1177/1352458517690617  0.357
2017 Haghikia A, Dendrou CA, Schneider R, Grüter T, Postert T, Matzke M, Stephanik H, Fugger L, Gold R. Severe B-cell-mediated CNS disease secondary to alemtuzumab therapy. The Lancet. Neurology. 16: 104-106. PMID 28102146 DOI: 10.1016/S1474-4422(16)30382-9  0.302
2016 Faissner S, Lukas C, Reinacher-Schick A, Tannapfel A, Gold R, Kleiter I. Amphiphysin-positive paraneoplastic myelitis and stiff-person syndrome. Neurology(R) Neuroimmunology & Neuroinflammation. 3: e285. PMID 27734022 DOI: 10.1212/Nxi.0000000000000285  0.326
2016 Haghikia A, Gold R. Active immunotherapy may delay disability in progressive MS. Journal of Neurology, Neurosurgery, and Psychiatry. PMID 27683917 DOI: 10.1136/Jnnp-2016-314377  0.364
2016 Giovannoni G, Kappos L, Gold R, Khatri BO, Selmaj K, Umans K, Greenberg SJ, Sweetser M, Elkins J, McCroskery P. Safety and tolerability profile of daclizumab in patients with relapsing-remitting multiple sclerosis: An integrated analysis of clinical studies. Multiple Sclerosis and Related Disorders. 9: 36-46. PMID 27645341 DOI: 10.1016/J.Msard.2016.05.010  0.369
2016 Hoepner R, Kolb EM, Dahlhaus S, Hellwig K, Adams O, Kleiter I, Salmen A, Schneider R, Lukas C, Chan A, Berger JR, Gold R. Predictors of severity and functional outcome in natalizumab-associated progressive multifocal leukoencephalopathy. Multiple Sclerosis (Houndmills, Basingstoke, England). PMID 27600113 DOI: 10.1177/1352458516667241  0.326
2016 Vermersch P, Smets L, Gold R. Conclusions: Calls to action for improving the life of MS patients and their families. Multiple Sclerosis (Houndmills, Basingstoke, England). 22: 71-7. PMID 27465617 DOI: 10.1177/1352458516650738  0.336
2016 Gold R, Toumi M, Meesen B, Fogarty E. The payer's perspective: What is the burden of MS and how should the patient's perspective be integrated in health technology assessment conducted for taking decisions on access to care and treatment? Multiple Sclerosis (Houndmills, Basingstoke, England). 22: 60-70. PMID 27465616 DOI: 10.1177/1352458516650743  0.323
2016 Vermersch P, Berger T, Gold R, Lukas C, Rovira A, Meesen B, Chard D, Comabella M, Palace J, Trojano M. The clinical perspective: How to personalise treatment in MS and how may biomarkers including imaging contribute to this? Multiple Sclerosis (Houndmills, Basingstoke, England). 22: 18-33. PMID 27465613 DOI: 10.1177/1352458516650739  0.375
2016 Vermersch P, Smets L, Gold R. Introduction: Do we need multi-stakeholder colloquia in MS? Multiple Sclerosis (Houndmills, Basingstoke, England). 22: 4-8. PMID 27465611 DOI: 10.1177/1352458516650740  0.319
2016 Andlauer TF, Buck D, Antony G, Bayas A, Bechmann L, Berthele A, Chan A, Gasperi C, Gold R, Graetz C, Haas J, Hecker M, Infante-Duarte C, Knop M, Kümpfel T, et al. Novel multiple sclerosis susceptibility loci implicated in epigenetic regulation. Science Advances. 2: e1501678. PMID 27386562 DOI: 10.1126/Sciadv.1501678  0.32
2016 Faissner S, Nikolayczik J, Chan A, Gold R, Yoon MS, Haghikia A. Immunoadsorption in patients with neuromyelitis optica spectrum disorder. Therapeutic Advances in Neurological Disorders. 9: 281-6. PMID 27366234 DOI: 10.1177/1756285616646332  0.317
2016 Otero-Romero S, Sastre-Garriga J, Comi G, Hartung HP, Soelberg Sørensen P, Thompson AJ, Vermersch P, Gold R, Montalban X. Pharmacological management of spasticity in multiple sclerosis: Systematic review and consensus paper. Multiple Sclerosis (Houndmills, Basingstoke, England). PMID 27207462 DOI: 10.1177/1352458516643600  0.351
2016 Gold R, Arnold DL, Bar-Or A, Hutchinson M, Kappos L, Havrdova E, MacManus DG, Yousry TA, Pozzilli C, Selmaj K, Sweetser MT, Zhang R, Yang M, Potts J, Novas M, et al. Long-term effects of delayed-release dimethyl fumarate in multiple sclerosis: Interim analysis of ENDORSE, a randomized extension study. Multiple Sclerosis (Houndmills, Basingstoke, England). PMID 27207449 DOI: 10.1177/1352458516649037  0.309
2016 Massa MG, Gisevius B, Hirschberg S, Hinz L, Schmidt M, Gold R, Prochnow N, Haghikia A. Multiple Sclerosis Patient-Specific Primary Neurons Differentiated from Urinary Renal Epithelial Cells via Induced Pluripotent Stem Cells. Plos One. 11: e0155274. PMID 27158987 DOI: 10.1371/Journal.Pone.0155274  0.307
2016 Kleiter I, Ayzenberg I, Araki M, Yamamura T, Gold R. Tocilizumab, MS, and NMOSD. Multiple Sclerosis (Houndmills, Basingstoke, England). PMID 27068554 DOI: 10.1177/1352458516643395  0.328
2016 Faissner S, Nikolayczik J, Chan A, Hellwig K, Gold R, Yoon MS, Haghikia A. Plasmapheresis and immunoadsorption in patients with steroid refractory multiple sclerosis relapses. Journal of Neurology. PMID 27039388 DOI: 10.1007/S00415-016-8105-4  0.362
2016 Jörg S, Kissel J, Manzel A, Kleinewietfeld M, Haghikia A, Gold R, Müller DN, Linker RA. High salt drives Th17 responses in experimental autoimmune encephalomyelitis without impacting myeloid dendritic cells. Experimental Neurology. 279: 212-222. PMID 26976739 DOI: 10.1016/J.Expneurol.2016.03.010  0.306
2016 Recke A, Oei A, Hübner F, Fechner K, Graf J, Hagenah J, May C, Woitalla D, Salmen A, Zillikens D, Gold R, Schlumberger W, Schmidt E. Parkinson's disease and multiple sclerosis are not associated with autoantibodies against structural proteins of the dermal-epidermal junction. The British Journal of Dermatology. PMID 26972435 DOI: 10.1111/Bjd.14538  0.335
2016 Grüter T, Strassburger-Krogias K, Hoepner R, Schroeder C, Haller S, Gold R, Krogias C. Basal ganglia alterations appearing in transcranial sonography prior to MRI in a patient with Creutzfeld-Jacob Disease. Journal of the Neurological Sciences. 362: 339-40. PMID 26944174 DOI: 10.1016/J.Jns.2016.02.010  0.301
2016 Gold R, Giovannoni G, Phillips JT, Fox RJ, Zhang A, Marantz JL. Sustained Effect of Delayed-Release Dimethyl Fumarate in Newly Diagnosed Patients with Relapsing-Remitting Multiple Sclerosis: 6-Year Interim Results From an Extension of the DEFINE and CONFIRM Studies. Neurology and Therapy. PMID 26932146 DOI: 10.1007/S40120-016-0042-8  0.344
2016 Klotz L, Berthele A, Brück W, Chan A, Flachenecker P, Gold R, Haghikia A, Hellwig K, Hemmer B, Hohlfeld R, Korn T, Kümpfel T, Lang M, Limmroth V, Linker RA, et al. [Monitoring of blood parameters under course-modified MS therapy : Substance-specific relevance and current recommendations for action]. Der Nervenarzt. PMID 26927677 DOI: 10.1007/S00115-016-0077-1  0.371
2016 Melzer N, Ruck T, Fuhr P, Gold R, Hohlfeld R, Marx A, Melms A, Tackenberg B, Schalke B, Schneider-Gold C, Zimprich F, Meuth SG, Wiendl H. Clinical features, pathogenesis, and treatment of myasthenia gravis: a supplement to the Guidelines of the German Neurological Society. Journal of Neurology. PMID 26886206 DOI: 10.1007/S00415-016-8045-Z  0.32
2016 Radue E, Giovannoni G, Gold R, Selmaj K, Havrdova E, Stefoski D, Sprenger T, Montalban X, Riester K, Ozen G. Daclizumab Hyp In Multiple Sclerosis: 3-Year Results From Selected Journal of Neurology, Neurosurgery, and Psychiatry. 87. DOI: 10.1136/Jnnp-2016-315106.141  0.305
2016 Fatoba O, Kloster E, Saft C, Gold R, Arning L, Ellrichmann G. L22 Intranasal application of NPY and NPY13–36 ameliorate disease pathology in R6/2 mouse model of huntington’s disease Journal of Neurology, Neurosurgery, and Psychiatry. 87. DOI: 10.1136/Jnnp-2016-314597.277  0.716
2016 Ellrichmann G, Blusch A, Fatoba O, Brunner J, Pitarokoili K, Hayardeny L, Saft C, Gold R. L7 Laquinimod in the R6/2 mouse model of huntington’s disease Journal of Neurology, Neurosurgery, and Psychiatry. 87. DOI: 10.1136/Jnnp-2016-314597.262  0.725
2016 Fatoba O, Ellrichmann G, Saft C, Kloster E, Gold R, Arning L. Activation of neuropeptide-Y2 receptor mediates neuroprotection in cellular model of Huntington's disease Neuropeptides. 55: 5. DOI: 10.1016/J.Npep.2015.11.012  0.702
2015 Schrewe L, Lill CM, Liu T, Salmen A, Gerdes LA, Guillot-Noel L, Akkad DA, Blaschke P, Graetz C, Hoffjan S, Kroner A, Demir S, Böhme A, Rieckmann P, ElAli A, ... ... Gold R, et al. Investigation of sex-specific effects of apolipoprotein E on severity of EAE and MS. Journal of Neuroinflammation. 12: 234. PMID 26669675 DOI: 10.1186/S12974-015-0429-Y  0.363
2015 Pitarokoili K, Ambrosius B, Meyer D, Schrewe L, Gold R. Dimethyl Fumarate Ameliorates Lewis Rat Experimental Autoimmune Neuritis and Mediates Axonal Protection. Plos One. 10: e0143416. PMID 26618510 DOI: 10.1371/Journal.Pone.0143416  0.325
2015 Kleiter I, Gold R. Present and Future Therapies in Neuromyelitis Optica Spectrum Disorders. Neurotherapeutics : the Journal of the American Society For Experimental Neurotherapeutics. PMID 26597098 DOI: 10.1007/S13311-015-0400-8  0.336
2015 Faissner S, Hoepner R, Lukas C, Chan A, Gold R, Ellrichmann G. Tumefactive multiple sclerosis lesions in two patients after cessation of fingolimod treatment. Therapeutic Advances in Neurological Disorders. 8: 233-8. PMID 26557898 DOI: 10.1177/1756285615594575  0.362
2015 Giovannoni G, Gold R, Fox RJ, Kappos L, Kita M, Yang M, Sarda SP, Zhang R, Viglietta V, Havrdova E. Relapses Requiring Intravenous Steroid Use and Multiple-Sclerosis-Related Hospitalizations: Integrated Analysis of the Delayed-Release Dimethyl Fumarate Phase III Studies. Clinical Therapeutics. PMID 26526385 DOI: 10.1016/J.Clinthera.2015.09.011  0.309
2015 Haghikia A, Jörg S, Duscha A, Berg J, Manzel A, Waschbisch A, Hammer A, Lee DH, May C, Wilck N, Balogh A, Ostermann AI, Schebb NH, Akkad DA, Grohme DA, ... ... Gold R, et al. Dietary Fatty Acids Directly Impact Central Nervous System Autoimmunity via the Small Intestine. Immunity. 43: 817-29. PMID 26488817 DOI: 10.1016/J.Immuni.2015.09.007  0.328
2015 Phillips JT, Selmaj K, Gold R, Fox RJ, Havrdova E, Giovannoni G, Abourjaily H, Pace A, Novas M, Hotermans C, Viglietta V, Meltzer L. Clinical Significance of Gastrointestinal and Flushing Events in Patients with Multiple Sclerosis Treated with Delayed-Release Dimethyl Fumarate. International Journal of Ms Care. 17: 236-43. PMID 26472945 DOI: 10.7224/1537-2073.2014-069  0.343
2015 Hellwig K, Rockhoff M, Herbstritt S, Borisow N, Haghikia A, Elias-Hamp B, Menck S, Gold R, Langer-Gould A. Exclusive Breastfeeding and the Effect on Postpartum Multiple Sclerosis Relapses. Jama Neurology. 72: 1132-8. PMID 26322399 DOI: 10.1001/Jamaneurol.2015.1806  0.339
2015 Kolber P, Luessi F, Meuth SG, Klotz L, Korn T, Trebst C, Tackenberg B, Kieseier B, Kümpfel T, Fleischer V, Tumani H, Wildemann B, Lang M, Flachenecker P, Meier U, ... ... Gold R, et al. [Current aspects of therapy conversion for multiple sclerosis]. Der Nervenarzt. 86: 1236-47. PMID 26269289 DOI: 10.1007/S00115-015-4368-8  0.365
2015 Demir S, Heckers S, Pedreiturria X, Hess D, Trampe AK, Chan A, Gold R. Low dose fumaric acid esters are effective in a mouse model of spontaneous chronic encephalomyelitis. Journal of Neuroimmunology. 285: 16-21. PMID 26198914 DOI: 10.1016/J.Jneuroim.2015.05.010  0.303
2015 Stasiolek M, Linker RA, Hayardeny L, Bar Ilan O, Gold R. Immune parameters of patients treated with laquinimod, a novel oral therapy for the treatment of multiple sclerosis: results from a double-blind placebo-controlled study. Immunity, Inflammation and Disease. 3: 45-55. PMID 26029365 DOI: 10.1002/Iid3.42  0.384
2015 Akkad DA, Olischewsky A, Reiner F, Hellwig K, Esser S, Epplen JT, Curk T, Gold R, Haghikia A. Combinations of susceptibility genes are associated with higher risk for multiple sclerosis and imply disease course specificity. Plos One. 10: e0127632. PMID 26011527 DOI: 10.1371/Journal.Pone.0127632  0.332
2015 Bellenberg B, Schneider R, Weiler F, Suchan B, Haghikia A, Hoffjan S, Gold R, Köster O, Lukas C. Cervical cord area is associated with infratentorial grey and white matter volume predominantly in relapsing-remitting multiple sclerosis: A study using semi-automated cord volumetry and voxel-based morphometry. Multiple Sclerosis and Related Disorders. 4: 264-72. PMID 26008944 DOI: 10.1016/J.Msard.2015.04.003  0.303
2015 Ringelstein M, Ayzenberg I, Harmel J, Lauenstein AS, Lensch E, Stögbauer F, Hellwig K, Ellrichmann G, Stettner M, Chan A, Hartung HP, Kieseier B, Gold R, Aktas O, Kleiter I. Long-term Therapy With Interleukin 6 Receptor Blockade in Highly Active Neuromyelitis Optica Spectrum Disorder. Jama Neurology. 72: 756-63. PMID 25985228 DOI: 10.1001/Jamaneurol.2015.0533  0.306
2015 Krogias C, Gold R, Chan A, Triantafyllou N, Voumvourakis K, Tsivgoulis G. Brain Hyperechogenicities are not Associated with Venous Insufficiency in Multiple Sclerosis: A Pilot Neurosonology Study. Journal of Neuroimaging : Official Journal of the American Society of Neuroimaging. PMID 25891137 DOI: 10.1111/Jon.12248  0.323
2015 Metz I, Traffehn S, Straßburger-Krogias K, Keyvani K, Bergmann M, Nolte K, Weber MS, Bartsch T, Gold R, Brück W. Glial cells express nuclear nrf2 after fumarate treatment for multiple sclerosis and psoriasis. Neurology® Neuroimmunology & Neuroinflammation. 2: e99. PMID 25866832 DOI: 10.1212/Nxi.0000000000000099  0.366
2015 Kohlmann R, Salmen A, Chan A, Knabbe C, Diekmann J, Brockmeyer N, Skaletz-Rorowski A, Michalik C, Gold R, Überla K. Serological evidence of increased susceptibility to varicella-zoster virus reactivation or reinfection in natalizumab-treated patients with multiple sclerosis. Multiple Sclerosis (Houndmills, Basingstoke, England). PMID 25828755 DOI: 10.1177/1352458515576984  0.352
2015 Novkovic T, Shchyglo O, Gold R, Manahan-Vaughan D. Hippocampal function is compromised in an animal model of multiple sclerosis. Neuroscience. PMID 25795599 DOI: 10.1016/J.Neuroscience.2015.03.008  0.314
2015 Viglietta V, Miller D, Bar-Or A, Phillips JT, Arnold DL, Selmaj K, Kita M, Hutchinson M, Yang M, Zhang R, Dawson KT, Sheikh SI, Fox RJ, Gold R. Efficacy of delayed-release dimethyl fumarate in relapsing-remitting multiple sclerosis: integrated analysis of the phase 3 trials. Annals of Clinical and Translational Neurology. 2: 103-18. PMID 25750916 DOI: 10.1002/Acn3.148  0.348
2015 Tsivgoulis G, Faissner S, Voumvourakis K, Katsanos AH, Triantafyllou N, Grigoriadis N, Gold R, Krogias C. "Liberation treatment" for chronic cerebrospinal venous insufficiency in multiple sclerosis: the truth will set you free. Brain and Behavior. 5: 3-12. PMID 25722945 DOI: 10.1002/Brb3.297  0.361
2015 Akkad DA, Bellenberg B, Esser S, Weiler F, Epplen JT, Gold R, Lukas C, Haghikia A. Multiple sclerosis risk loci correlate with cervical cord atrophy and may explain the course of disability. Neurogenetics. 16: 161-8. PMID 25620546 DOI: 10.1007/S10048-015-0438-0  0.337
2015 Kappos L, Giovannoni G, Gold R, Phillips JT, Arnold DL, Hotermans C, Zhang A, Viglietta V, Fox RJ. Time course of clinical and neuroradiological effects of delayed-release dimethyl fumarate in multiple sclerosis. European Journal of Neurology : the Official Journal of the European Federation of Neurological Societies. 22: 664-71. PMID 25557371 DOI: 10.1111/Ene.12624  0.327
2015 Skripuletz T, Manzel A, Gropengießer K, Schäfer N, Gudi V, Singh V, Salinas Tejedor L, Jörg S, Hammer A, Voss E, Vulinovic F, Degen D, Wolf R, Lee DH, Pul R, ... ... Gold R, et al. Pivotal role of choline metabolites in remyelination. Brain : a Journal of Neurology. 138: 398-413. PMID 25524711 DOI: 10.1093/Brain/Awu358  0.354
2015 Grey Née Cotte S, Salmen Née Stroet A, von Ahsen N, Starck M, Winkelmann A, Zettl UK, Comabella M, Montalban X, Zipp F, Fleischer V, Kruse N, Gold R, Chan A. Lack of efficacy of mitoxantrone in primary progressive Multiple Sclerosis irrespective of pharmacogenetic factors: a multi-center, retrospective analysis. Journal of Neuroimmunology. 278: 277-9. PMID 25468777 DOI: 10.1016/J.Jneuroim.2014.11.017  0.354
2015 Warnke C, Stettner M, Lehmensiek V, Dehmel T, Mausberg AK, von Geldern G, Gold R, Kümpfel T, Hohlfeld R, Mäurer M, Stangel M, Straeten V, Limmroth V, Weber T, Kleinschnitz C, et al. Natalizumab exerts a suppressive effect on surrogates of B cell function in blood and CSF. Multiple Sclerosis (Houndmills, Basingstoke, England). 21: 1036-44. PMID 25392339 DOI: 10.1177/1352458514556296  0.349
2015 Krogias C, Bellenberg B, Prehn C, Schneider R, Meves SH, Gold R, Lukas C, Schneider-Gold C. Evaluation of CNS involvement in myotonic dystrophy type 1 and type 2 by transcranial sonography. Journal of Neurology. 262: 365-74. PMID 25385052 DOI: 10.1007/S00415-014-7566-6  0.313
2015 Kaufman M, Cree BA, De Sèze J, Fox RJ, Gold R, Hartung HP, Jeffery D, Kappos L, Montalbán X, Weinstock-Guttman B, Ticho B, Duda P, Pace A, Campagnolo D. Radiologic MS disease activity during natalizumab treatment interruption: findings from RESTORE. Journal of Neurology. 262: 326-36. PMID 25381458 DOI: 10.1007/S00415-014-7558-6  0.334
2015 Thöne J, Kollar S, Nousome D, Ellrichmann G, Kleiter I, Gold R, Hellwig K. Serum anti-Müllerian hormone levels in reproductive-age women with relapsing-remitting multiple sclerosis. Multiple Sclerosis (Houndmills, Basingstoke, England). 21: 41-7. PMID 25145691 DOI: 10.1177/1352458514540843  0.309
2015 Herbstritt S, Gold R, Hellwig K. Kinderwunsch und Multiple Sklerose Frauenheilkunde Up2date. 9: 133-151. DOI: 10.1055/S-0033-1358114  0.321
2014 Lee DH, Heidecke H, Schröder A, Paul F, Wachter R, Hoffmann R, Ellrichmann G, Dragun D, Waschbisch A, Stegbauer J, Klotz P, Gold R, Dechend R, Müller DN, Saft C, et al. Increase of angiotensin II type 1 receptor auto-antibodies in Huntington's disease. Molecular Neurodegeneration. 9: 49. PMID 25398321 DOI: 10.1186/1750-1326-9-49  0.371
2014 Hoepner R, Faissner S, Ellrichmann G, Schneider R, Gold R. Rituximab postprogressive multifocal leukoencephalopathy: a Feasible therapeutic option in selected cases. Therapeutic Advances in Neurological Disorders. 7: 289-91. PMID 25371711 DOI: 10.1177/1756285614556287  0.406
2014 Strassburger-Krogias K, Ellrichmann G, Krogias C, Altmeyer P, Chan A, Gold R. Fumarate treatment in progressive forms of multiple sclerosis: first results of a single-center observational study. Therapeutic Advances in Neurological Disorders. 7: 232-8. PMID 25342977 DOI: 10.1177/1756285614544466  0.382
2014 Arnold DL, Gold R, Kappos L, Bar-Or A, Giovannoni G, Selmaj K, Yang M, Zhang R, Stephan M, Sheikh SI, Dawson KT. Magnetization transfer ratio in the delayed-release dimethyl fumarate DEFINE study. Journal of Neurology. 261: 2429-37. PMID 25270680 DOI: 10.1007/S00415-014-7504-7  0.305
2014 Pitarokoili K, Ambrosius B, Schrewe L, Hayardeny L, Hayden M, Gold R. Laquinimod exerts strong clinical and immunomodulatory effects in Lewis rat experimental autoimmune neuritis. Journal of Neuroimmunology. 274: 38-45. PMID 25005118 DOI: 10.1016/J.Jneuroim.2014.06.012  0.328
2014 Manzel A, Domenig O, Ambrosius B, Kovacs A, Stegbauer J, Poglitsch M, Mueller DN, Gold R, Linker RA. Angiotensin IV is induced in experimental autoimmune encephalomyelitis but fails to influence the disease. Journal of Neuroimmune Pharmacology : the Official Journal of the Society On Neuroimmune Pharmacology. 9: 533-43. PMID 24854706 DOI: 10.1007/S11481-014-9548-Y  0.337
2014 Haghikia A, Langer-Gould A, Rellensmann G, Schneider H, Tenenbaum T, Elias-Hamp B, Menck S, Zimmermann J, Herbstritt S, Marziniak M, Kümpfel T, Meinl I, Plavina T, Gold R, Hellwig K. Natalizumab use during the third trimester of pregnancy. Jama Neurology. 71: 891-5. PMID 24821217 DOI: 10.1001/Jamaneurol.2014.209  0.301
2014 Gold R, Fugger L. Multiple sclerosis: insights into pathophysiology and novel therapeutic avenues. Experimental Neurology. 262: 1. PMID 24751800 DOI: 10.1016/J.Expneurol.2014.04.012  0.366
2014 Reick C, Ellrichmann G, Thöne J, Scannevin RH, Saft C, Linker RA, Gold R. Neuroprotective dimethyl fumarate synergizes with immunomodulatory interferon beta to provide enhanced axon protection in autoimmune neuroinflammation. Experimental Neurology. 257: 50-6. PMID 24731948 DOI: 10.1016/J.Expneurol.2014.04.003  0.335
2014 Warnke C, von Geldern G, Markwerth P, Dehmel T, Hoepner R, Gold R, Pawlita M, Kümpfel T, Mäurer M, Stangel M, Wegner F, Hohlfeld R, Straeten V, Limmroth V, Weber T, et al. Cerebrospinal fluid JC virus antibody index for diagnosis of natalizumab-associated progressive multifocal leukoencephalopathy. Annals of Neurology. 76: 792-801. PMID 24729444 DOI: 10.1002/Ana.24153  0.305
2014 Giovannoni G, Gold R, Selmaj K, Havrdova E, Montalban X, Radue EW, Stefoski D, McNeill M, Amaravadi L, Sweetser M, Elkins J, O'Neill G. Daclizumab high-yield process in relapsing-remitting multiple sclerosis (SELECTION): a multicentre, randomised, double-blind extension trial. The Lancet. Neurology. 13: 472-81. PMID 24656609 DOI: 10.1016/S1474-4422(14)70039-0  0.326
2014 Haghikia A, Gold R. Multiple sclerosis: TOWER confirms the efficacy of oral teriflunomide in MS. Nature Reviews. Neurology. 10: 183-4. PMID 24638132 DOI: 10.1038/Nrneurol.2014.42  0.39
2014 Rose-John S, Gold R. Devic disease: translational medicine at work. Neurology. 82: 1294-5. PMID 24634457 DOI: 10.1212/Wnl.0000000000000322  0.307
2014 Tsivgoulis G, Sergentanis TN, Chan A, Voumvourakis K, Triantafyllou N, Psaltopoulou T, Gold R, Krogias C. Chronic cerebrospinal venous insufficiency and multiple sclerosis: a comprehensive meta-analysis of case-control studies. Therapeutic Advances in Neurological Disorders. 7: 114-36. PMID 24587827 DOI: 10.1177/1756285613499425  0.348
2014 Salmen A, Gold R. Mode of action and clinical studies with fumarates in multiple sclerosis. Experimental Neurology. 262: 52-6. PMID 24568735 DOI: 10.1016/J.Expneurol.2014.02.015  0.405
2014 Chuang WY, Ströbel P, Bohlender-Willke AL, Rieckmann P, Nix W, Schalke B, Gold R, Opitz A, Klinker E, Inoue M, Müller-Hermelink HK, Saruhan-Direskeneli G, Bugert P, Willcox N, Marx A. Late-onset myasthenia gravis - CTLA4(low) genotype association and low-for-age thymic output of naïve T cells. Journal of Autoimmunity. 52: 122-9. PMID 24373506 DOI: 10.1016/J.Jaut.2013.12.006  0.305
2014 Salmen A, Gold R, Chan A. Management of disease-modifying treatments in neurological autoimmune diseases of the central nervous system. Clinical and Experimental Immunology. 176: 135-48. PMID 24358961 DOI: 10.1111/Cei.12258  0.303
2014 Kappos L, Gold R, Arnold DL, Bar-Or A, Giovannoni G, Selmaj K, Sarda SP, Agarwal S, Zhang A, Sheikh SI, Seidman E, Dawson KT. Quality of life outcomes with BG-12 (dimethyl fumarate) in patients with relapsing-remitting multiple sclerosis: the DEFINE study. Multiple Sclerosis (Houndmills, Basingstoke, England). 20: 243-52. PMID 24150779 DOI: 10.1177/1352458513507817  0.337
2014 Herbstritt S, Gold R, Hellwig K. Kinderwunsch und Multiple Sklerose Aktuelle Neurologie. 41: 476-490. DOI: 10.1055/S-0033-1337051  0.321
2014 Ellrichmann G, Reick C, Saft C, Thöne J, Hayardeny L, Gold R. Laquinimod treatment in a mouse model of Huntington's disease: A new neuroprotective therapy? Journal of Neuroimmunology. 275: 217-218. DOI: 10.1016/J.Jneuroim.2014.08.583  0.331
2014 Ellrichmann G, Straßburger-krogias K, Krogias C, Gold R. Fumarate treatment in patients with progressive forms of MS: First results of a single-center observational study Journal of Neuroimmunology. 275: 217. DOI: 10.1016/J.Jneuroim.2014.08.582  0.372
2013 Gold R, Oreja-Guevara C. Advances in the management of multiple sclerosis spasticity: multiple sclerosis spasticity guidelines. Expert Review of Neurotherapeutics. 13: 55-9. PMID 24289845 DOI: 10.1586/14737175.2013.865880  0.365
2013 Gold R. Multiple sclerosis spasticity epidemiology--key publications. Expert Review of Neurotherapeutics. 13: 45-6. PMID 24289842 DOI: 10.1586/14737175.2013.865874  0.317
2013 Gold R. New insights into multiple sclerosis and advances in multiple sclerosis spasticity management. Expert Review of Neurotherapeutics. 13: 1-2. PMID 24289835 DOI: 10.1586/14737175.2013.865865  0.328
2013 Thöne J, Gold R. Review of laquinimod and its therapeutic potential in multiple sclerosis. Expert Opinion On Pharmacotherapy. 14: 2545-52. PMID 24215556 DOI: 10.1517/14656566.2013.848855  0.4
2013 Zipp F, Gold R, Wiendl H. Identification of inflammatory neuronal injury and prevention of neuronal damage in multiple sclerosis: hope for novel therapies? Jama Neurology. 70: 1569-74. PMID 24145957 DOI: 10.1001/Jamaneurol.2013.4391  0.353
2013 Prochnow N, Gold R, Haghikia A. An electrophysiologic approach to quantify impaired synaptic transmission and plasticity in experimental autoimmune encephalomyelitis. Journal of Neuroimmunology. 264: 48-53. PMID 24090654 DOI: 10.1016/J.Jneuroim.2013.09.012  0.305
2013 Linker RA, Gold R. Dimethyl fumarate for treatment of multiple sclerosis: mechanism of action, effectiveness, and side effects. Current Neurology and Neuroscience Reports. 13: 394. PMID 24061646 DOI: 10.1007/S11910-013-0394-8  0.382
2013 Havrdova E, Hutchinson M, Kurukulasuriya NC, Raghupathi K, Sweetser MT, Dawson KT, Gold R. Oral BG-12 (dimethyl fumarate) for relapsing-remitting multiple sclerosis: a review of DEFINE and CONFIRM. Evaluation of: Gold R, Kappos L, Arnold D, et al. Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis. N Engl J Med 2012;367:1098-107; and Fox RJ, Miller DH, Phillips JT, et al. Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis. N Engl J Med 2012;367:1087-97. Expert Opinion On Pharmacotherapy. 14: 2145-56. PMID 23971970 DOI: 10.1517/14656566.2013.826190  0.372
2013 Lee DH, Stangel M, Gold R, Linker RA. The fumaric acid ester BG-12: a new option in MS therapy. Expert Review of Neurotherapeutics. 13: 951-8. PMID 23944289 DOI: 10.1586/14737175.2013.814958  0.353
2013 Schwab N, Schneider-Hohendorf T, Posevitz V, Breuer J, Göbel K, Windhagen S, Brochet B, Vermersch P, Lebrun-Frenay C, Posevitz-Fejfár A, Capra R, Imberti L, Straeten V, Haas J, Wildemann B, ... ... Gold R, et al. L-selectin is a possible biomarker for individual PML risk in natalizumab-treated MS patients. Neurology. 81: 865-71. PMID 23925765 DOI: 10.1212/Wnl.0B013E3182A351Fb  0.352
2013 Brück W, Gold R, Lund BT, Oreja-Guevara C, Prat A, Spencer CM, Steinman L, Tintoré M, Vollmer TL, Weber MS, Weiner LP, Ziemssen T, Zamvil SS. Therapeutic decisions in multiple sclerosis: moving beyond efficacy. Jama Neurology. 70: 1315-24. PMID 23921521 DOI: 10.1001/Jamaneurol.2013.3510  0.314
2013 Harbo HF, Gold R, Tintoré M. Sex and gender issues in multiple sclerosis. Therapeutic Advances in Neurological Disorders. 6: 237-48. PMID 23858327 DOI: 10.1177/1756285613488434  0.301
2013 Stroet A, Linker RA, Gold R. Advancing therapeutic options in multiple sclerosis with neuroprotective properties. Journal of Neural Transmission (Vienna, Austria : 1996). 120: S49-53. PMID 23720188 DOI: 10.1007/S00702-013-1037-6  0.381
2013 Dahlhaus S, Hoepner R, Chan A, Kleiter I, Adams O, Lukas C, Hellwig K, Gold R. Disease course and outcome of 15 monocentrically treated natalizumab-associated progressive multifocal leukoencephalopathy patients. Journal of Neurology, Neurosurgery, and Psychiatry. 84: 1068-74. PMID 23606731 DOI: 10.1136/Jnnp-2013-304897  0.362
2013 Haghikia A, Hohlfeld R, Gold R, Fugger L. Therapies for multiple sclerosis: translational achievements and outstanding needs. Trends in Molecular Medicine. 19: 309-19. PMID 23582699 DOI: 10.1016/J.Molmed.2013.03.004  0.368
2013 Gold R, Giovannoni G, Selmaj K, Havrdova E, Montalban X, Radue EW, Stefoski D, Robinson R, Riester K, Rana J, Elkins J, O'Neill G. Daclizumab high-yield process in relapsing-remitting multiple sclerosis (SELECT): a randomised, double-blind, placebo-controlled trial. Lancet (London, England). 381: 2167-75. PMID 23562009 DOI: 10.1016/S0140-6736(12)62190-4  0.333
2013 Greenberg BM, Balcer L, Calabresi PA, Cree B, Cross A, Frohman T, Gold R, Havrdova E, Hemmer B, Kieseier BC, Lisak R, Miller A, Racke MK, Steinman L, Stuve O, et al. Interferon beta use and disability prevention in relapsing-remitting multiple sclerosis. Jama Neurology. 70: 248-51. PMID 23530268 DOI: 10.1001/Jamaneurol.2013.1017  0.325
2013 Ayzenberg I, Kleiter I, Schröder A, Hellwig K, Chan A, Yamamura T, Gold R. Interleukin 6 receptor blockade in patients with neuromyelitis optica nonresponsive to anti-CD20 therapy. Jama Neurology. 70: 394-7. PMID 23358868 DOI: 10.1001/Jamaneurol.2013.1246  0.318
2013 Lühder F, Gold R, Flügel A, Linker RA. Brain-derived neurotrophic factor in neuroimmunology: lessons learned from multiple sclerosis patients and experimental autoimmune encephalomyelitis models. Archivum Immunologiae Et Therapiae Experimentalis. 61: 95-105. PMID 23283517 DOI: 10.1007/S00005-012-0211-0  0.37
2013 Havla J, Tackenberg B, Hellwig K, Meinl I, Krumbholz M, Seitz F, Eienbröker C, Gold R, Hohlfeld R, Kleiter I, Kümpfel T. Fingolimod reduces recurrence of disease activity after natalizumab withdrawal in multiple sclerosis. Journal of Neurology. 260: 1382-7. PMID 23266894 DOI: 10.1007/S00415-012-6808-8  0.397
2013 Bayas A, Gold R, Naumann M. Long-term treatment of Lewis-Sumner syndrome with subcutaneous immunoglobulin infusions. Journal of the Neurological Sciences. 324: 53-6. PMID 23095259 DOI: 10.1016/J.Jns.2012.09.033  0.3
2013 Stangel M, Baumann U, Borte M, Fasshauer M, Hensel M, Huscher D, Kirch W, Pittrow D, Reiser M, Gold R. Treatment of neurological autoimmune diseases with immunoglobulins: first insights from the prospective SIGNS registry. Journal of Clinical Immunology. 33: S67-71. PMID 22976553 DOI: 10.1007/S10875-012-9789-6  0.338
2013 Décard BF, Haghikia A, Tönnes C, Thöne J, Lukas C, Chan A, Gold R. Natalizumab-associated reversible encephalopathy syndrome mimicking progressive multifocal leukoencephalopathy. Multiple Sclerosis (Houndmills, Basingstoke, England). 19: 249-51. PMID 22596228 DOI: 10.1177/1352458512448268  0.346
2013 Burek M, Haghikia A, Gold R, Roewer N, Chan A, Frster CY. Differential Cytokine Release from Brain Microvascular Endothelial Cells Treated with Dexamethasone and Multiple Sclerosis Patient Sera Journal of Steroids & Hormonal Science. 5: 1-8. DOI: 10.4172/2157-7536.1000128  0.388
2012 Lee DH, Gold R, Linker RA. Mechanisms of Oxidative Damage in Multiple Sclerosis and Neurodegenerative Diseases: Therapeutic Modulation via Fumaric Acid Esters. International Journal of Molecular Sciences. 13: 11783-803. PMID 23109883 DOI: 10.3390/Ijms130911783  0.373
2012 Brück W, Popescu B, Lucchinetti CF, Markovic-Plese S, Gold R, Thal DR, Metz I. Neuromyelitis optica lesions may inform multiple sclerosis heterogeneity debate. Annals of Neurology. 72: 385-94. PMID 23034911 DOI: 10.1002/Ana.23621  0.339
2012 Gold R, Kappos L, Arnold DL, Bar-Or A, Giovannoni G, Selmaj K, Tornatore C, Sweetser MT, Yang M, Sheikh SI, Dawson KT. Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis. The New England Journal of Medicine. 367: 1098-107. PMID 22992073 DOI: 10.1056/Nejmoa1114287  0.349
2012 Hellwig K, Haghikia A, Rockhoff M, Gold R. Multiple sclerosis and pregnancy: experience from a nationwide database in Germany. Therapeutic Advances in Neurological Disorders. 5: 247-53. PMID 22973421 DOI: 10.1177/1756285612453192  0.319
2012 Décard BF, von Ahsen N, Grunwald T, Streit F, Stroet A, Niggemeier P, Schottstedt V, Riggert J, Gold R, Chan A. Low vitamin D and elevated immunoreactivity against Epstein-Barr virus before first clinical manifestation of multiple sclerosis. Journal of Neurology, Neurosurgery, and Psychiatry. 83: 1170-3. PMID 22888143 DOI: 10.1136/Jnnp-2012-303068  0.306
2012 Mentzer D, Prestel J, Adams O, Gold R, Hartung HP, Hengel H, Kieseier BC, Ludwig WD, Keller-Stanislawski B. Case definition for progressive multifocal leukoencephalopathy following treatment with monoclonal antibodies. Journal of Neurology, Neurosurgery, and Psychiatry. 83: 927-33. PMID 22807558 DOI: 10.1136/Jnnp-2012-302478  0.308
2012 Gregory AP, Dendrou CA, Attfield KE, Haghikia A, Xifara DK, Butter F, Poschmann G, Kaur G, Lambert L, Leach OA, Prömel S, Punwani D, Felce JH, Davis SJ, Gold R, et al. TNF receptor 1 genetic risk mirrors outcome of anti-TNF therapy in multiple sclerosis. Nature. 488: 508-11. PMID 22801493 DOI: 10.1038/Nature11307  0.349
2012 Srivastava R, Aslam M, Kalluri SR, Schirmer L, Buck D, Tackenberg B, Rothhammer V, Chan A, Gold R, Berthele A, Bennett JL, Korn T, Hemmer B. Potassium channel KIR4.1 as an immune target in multiple sclerosis. The New England Journal of Medicine. 367: 115-23. PMID 22784115 DOI: 10.1056/Nejmoa1110740  0.354
2012 Haghikia A, Décard BF, Hellwig K, Kraus P, Gold R. Wheels within wheels: multifocal autoimmune myelitis in a woman with Huntington's disease. Journal of Neurology. 259: 1973-5. PMID 22460588 DOI: 10.1007/S00415-012-6484-8  0.328
2012 Stroet A, Hemmelmann C, Starck M, Zettl U, Dörr J, Friedemann P, Paul F, Flachenecker P, Fleischer V, Zipp F, Nückel H, Kieseier BC, Ziegler A, Gold R, Chan A. Incidence of therapy-related acute leukaemia in mitoxantrone-treated multiple sclerosis patients in Germany. Therapeutic Advances in Neurological Disorders. 5: 75-9. PMID 22435072 DOI: 10.1177/1756285611433318  0.341
2012 Stroet A, Gold R, Chan A. Acute myeloid leukemia in Italian patients with multiple sclerosis treated with mitoxantrone. Neurology. 78: 933; author reply 93. PMID 22431743 DOI: 10.1212/01.Wnl.0000413366.14351.54  0.319
2012 Sørensen PS, Bertolotto A, Edan G, Giovannoni G, Gold R, Havrdova E, Kappos L, Kieseier BC, Montalban X, Olsson T. Risk stratification for progressive multifocal leukoencephalopathy in patients treated with natalizumab. Multiple Sclerosis (Houndmills, Basingstoke, England). 18: 143-52. PMID 22312009 DOI: 10.1177/1352458511435105  0.372
2012 Ayzenberg I, Lukas C, Trampe N, Gold R, Hellwig K. Value of MRI as a surrogate marker for PML in natalizumab long-term therapy. Journal of Neurology. 259: 1732-3. PMID 22289971 DOI: 10.1007/S00415-012-6426-5  0.352
2012 Rieckmann P, Heidenreich F, Sailer M, Zettl UK, Zessack N, Hartung HP, Gold R. Treatment de-escalation after mitoxantrone therapy: results of a phase IV, multicentre, open-label, randomized study of subcutaneous interferon beta-1a in patients with relapsing multiple sclerosis. Therapeutic Advances in Neurological Disorders. 5: 3-12. PMID 22276072 DOI: 10.1177/1756285611428503  0.349
2012 Gold R, Montalban X. Multiple sclerosis: more pieces of the immunological puzzle. The Lancet. Neurology. 11: 9-10. PMID 22172612 DOI: 10.1016/S1474-4422(11)70268-X  0.364
2012 Thöne J, Ellrichmann G, Seubert S, Peruga I, Lee DH, Conrad R, Hayardeny L, Comi G, Wiese S, Linker RA, Gold R. Modulation of autoimmune demyelination by laquinimod via induction of brain-derived neurotrophic factor. The American Journal of Pathology. 180: 267-74. PMID 22152994 DOI: 10.1016/J.Ajpath.2011.09.037  0.384
2012 Lee DH, Geyer E, Flach AC, Jung K, Gold R, Flügel A, Linker RA, Lühder F. Central nervous system rather than immune cell-derived BDNF mediates axonal protective effects early in autoimmune demyelination. Acta Neuropathologica. 123: 247-58. PMID 22009304 DOI: 10.1007/S00401-011-0890-3  0.316
2012 Schwab N, Höhn KG, Schneider-Hohendorf T, Metz I, Stenner MP, Jilek S, Du Pasquier RA, Gold R, Meuth SG, Ransohoff RM, Brück W, Wiendl H. Immunological and clinical consequences of treating a patient with natalizumab. Multiple Sclerosis (Houndmills, Basingstoke, England). 18: 335-44. PMID 21908480 DOI: 10.1177/1352458511421919  0.341
2012 Kappos L, Gold R, Miller DH, MacManus DG, Havrdova E, Limmroth V, Polman CH, Schmierer K, Yousry TA, Eraksoy M, Meluzinova E, Dufek M, Yang M, Dawson K, O'Neill GN. Effect of BG-12 on contrast-enhanced lesions in patients with relapsing--remitting multiple sclerosis: subgroup analyses from the phase 2b study. Multiple Sclerosis (Houndmills, Basingstoke, England). 18: 314-21. PMID 21878455 DOI: 10.1177/1352458511421054  0.33
2012 Arnold D, Gold R, Kappos L, Bar-Or A, Giovannoni G, Selmaj K, Yang M, Stephan M, Dawson K. Effects of BG-12 on Magnetization Transfer Ratio in Whole Brain and Normal-Appearing Brain Tissue: Findings from the DEFINE Study (S11.004) Neurology. 78. DOI: 10.1212/Wnl.78.1_Meetingabstracts.S11.004  0.313
2012 Giovannoni G, Gold R, Kappos L, Arnold D, Bar-Or A, Selmaj K, Zhang A, Sheikh S, Dawson K. BG-12 Increases the Proportion of Patients Free of Clinical and Radiologic Disease Activity in Relapsing-Remitting Multiple Sclerosis: Findings from the DEFINE Study (PD5.005) Neurology. 78. DOI: 10.1212/Wnl.78.1_Meetingabstracts.Pd5.005  0.347
2012 Agarwal S, Kappos L, Gold R, Arnold D, Bar-Or A, Giovannoni G, Selmaj K, Kong J, Sheikh S, Dawson K. Effects of BG-12 on Quality of Life in Patients with Relapsing-Remitting Multiple Sclerosis: Findings from the DEFINE Study (P07.102) Neurology. 78. DOI: 10.1212/Wnl.78.1_Meetingabstracts.P07.102  0.305
2012 Minwegen D, Poschmann G, Stuehler K, Faissner S, Haghikia A, Meyer H, Gold R, Chan A. Astrocytes Secrete Bridging Molecules That May Be Responsible for Increased Microglial Uptake of Apoptotic Inflammatory Cells (P07.090) Neurology. 78. DOI: 10.1212/Wnl.78.1_Meetingabstracts.P07.090  0.313
2012 Bar-Or A, Gold R, Kappos L, Arnold D, Giovannoni G, Selmaj K, O'Gorman J, Stephan M, Dawson K. Effect of BG-12 in Subgroups of Patients with Relapsing-Remitting Multiple Sclerosis: Findings from the DEFINE Study (P01.130) Neurology. 78. DOI: 10.1212/Wnl.78.1_Meetingabstracts.P01.130  0.351
2012 Décard BF, Thöne J, Gold R. Differenzialdiagnose der Multiplen Sklerose (MS) – MS Mimicks Aktuelle Neurologie. 39: 83-99. DOI: 10.1055/S-0032-1304603  0.337
2012 Kirch W, Stangel M, Pittrow D, Baumann U, Fasshauer M, Huscher D, Hensel M, Reiser M, Gold R, Borte M. Immunoglobulins for primary or secondary immunodeficiency or for immunomodulation in neurological autoimmune diseases: insights from the prospective SIGNS registry Journal of Public Health. 20: 289-296. DOI: 10.1007/S10389-012-0500-4  0.317
2011 Schweingruber N, Haine A, Tiede K, Karabinskaya A, van den Brandt J, Wüst S, Metselaar JM, Gold R, Tuckermann JP, Reichardt HM, Lühder F. Liposomal encapsulation of glucocorticoids alters their mode of action in the treatment of experimental autoimmune encephalomyelitis. Journal of Immunology (Baltimore, Md. : 1950). 187: 4310-8. PMID 21918186 DOI: 10.4049/Jimmunol.1101604  0.36
2011 Kappos L, Bates D, Edan G, Eraksoy M, Garcia-Merino A, Grigoriadis N, Hartung HP, Havrdová E, Hillert J, Hohlfeld R, Kremenchutzky M, Lyon-Caen O, Miller A, Pozzilli C, Ravnborg M, ... ... Gold R, et al. Natalizumab treatment for multiple sclerosis: updated recommendations for patient selection and monitoring. The Lancet. Neurology. 10: 745-58. PMID 21777829 DOI: 10.1016/S1474-4422(11)70149-1  0.363
2011 Yoon MS, Chan A, Gold R. Standard and escalating treatment of chronic inflammatory demyelinating polyradiculoneuropathy. Therapeutic Advances in Neurological Disorders. 4: 193-200. PMID 21694819 DOI: 10.1177/1756285611405564  0.324
2011 Hellwig K, Gold R. Progressive multifocal leukoencephalopathy and natalizumab. Journal of Neurology. 258: 1920-8. PMID 21647730 DOI: 10.1007/S00415-011-6116-8  0.371
2011 Hellwig K, Schimrigk S, Chan A, Epplen J, Gold R. A newborn with Pierre Robin sequence after preconceptional mitoxantrone exposure of a female with multiple sclerosis. Journal of the Neurological Sciences. 307: 164-5. PMID 21601225 DOI: 10.1016/J.Jns.2011.05.003  0.341
2011 Haghikia A, Perrech M, Pula B, Ruhrmann S, Potthoff A, Brockmeyer NH, Goelz S, Wiendl H, LindÃ¥ H, Ziemssen T, Baranzini SE, Käll TB, Bengel D, Olsson T, Gold R, et al. Functional energetics of CD4+-cellular immunity in monoclonal antibody-associated progressive multifocal leukoencephalopathy in autoimmune disorders. Plos One. 6: e18506. PMID 21533133 DOI: 10.1371/Journal.Pone.0018506  0.315
2011 Sørensen PS, Jensen PE, Haghikia A, Lundkvist M, Vedeler C, Sellebjerg F, Koch-Henriksen N, Fogdell-Hahn A, Myhr KM, Hillert J, Gold R. Occurrence of antibodies against natalizumab in relapsing multiple sclerosis patients treated with natalizumab. Multiple Sclerosis (Houndmills, Basingstoke, England). 17: 1074-8. PMID 21511692 DOI: 10.1177/1352458511404271  0.361
2011 Duddy M, Haghikia A, Cocco E, Eggers C, Drulovic J, Carmona O, Zéphir H, Gold R. Managing MS in a changing treatment landscape. Journal of Neurology. 258: 728-39. PMID 21437661 DOI: 10.1007/S00415-011-6009-X  0.388
2011 Schröder A, Klotz P, Lee DH, Gold R, Linker RA. Stability of cognitive functions under mitoxantrone therapy in patients with progressive multiple sclerosis: a pilot analysis. Clinical Neurology and Neurosurgery. 113: 527-30. PMID 21429658 DOI: 10.1016/J.Clineuro.2011.02.018  0.326
2011 Linker RA, Lee DH, Ryan S, van Dam AM, Conrad R, Bista P, Zeng W, Hronowsky X, Buko A, Chollate S, Ellrichmann G, Brück W, Dawson K, Goelz S, Wiese S, ... ... Gold R, et al. Fumaric acid esters exert neuroprotective effects in neuroinflammation via activation of the Nrf2 antioxidant pathway. Brain : a Journal of Neurology. 134: 678-92. PMID 21354971 DOI: 10.1093/Brain/Awq386  0.333
2011 Thöne J, Gold R. Laquinimod: a promising oral medication for the treatment of relapsing-remitting multiple sclerosis. Expert Opinion On Drug Metabolism & Toxicology. 7: 365-70. PMID 21306281 DOI: 10.1517/17425255.2011.556618  0.368
2011 Ellrichmann G, Petrasch-Parwez E, Lee DH, Reick C, Arning L, Saft C, Gold R, Linker RA. Efficacy of fumaric acid esters in the R6/2 and YAC128 models of Huntington's disease. Plos One. 6: e16172. PMID 21297955 DOI: 10.1371/Journal.Pone.0016172  0.33
2011 Peruga I, Hartwig S, Thöne J, Hovemann B, Gold R, Juckel G, Linker RA. Inflammation modulates anxiety in an animal model of multiple sclerosis. Behavioural Brain Research. 220: 20-9. PMID 21255614 DOI: 10.1016/J.Bbr.2011.01.018  0.325
2011 Gold R. Oral therapies for multiple sclerosis: a review of agents in phase III development or recently approved. Cns Drugs. 25: 37-52. PMID 21128693 DOI: 10.2165/11539820-000000000-00000  0.334
2011 Gold R, Wolinsky JS. Pathophysiology of multiple sclerosis and the place of teriflunomide. Acta Neurologica Scandinavica. 124: 75-84. PMID 20880295 DOI: 10.1111/J.1600-0404.2010.01444.X  0.427
2011 Gold R. Multiple Sklerose und die Bedeutung von Infektionen Aktuelle Neurologie. 38: 331-331. DOI: 10.1055/S-0031-1292815  0.304
2010 Gold R, Wolinsky JS, Amato MP, Comi G. Evolving expectations around early management of multiple sclerosis. Therapeutic Advances in Neurological Disorders. 3: 351-67. PMID 21179596 DOI: 10.1177/1756285610385608  0.372
2010 Meyer C, Ansorge N, Siglienti I, Salmen S, Stroet A, Nückel H, Dührsen U, Ritter PR, Schmidt WE, Gold R, Chan A. [Mitoxantrone-related acute leukemia by multiple sclerosis. Case report and practical approach by unclear cytopenia]. Der Nervenarzt. 81: 1483-9. PMID 21079910 DOI: 10.1007/S00115-010-3041-5  0.337
2010 Schroeder A, Linker RA, Lukas C, Kraus PH, Gold R. Successful treatment of cerebellar ataxia and tremor in multiple sclerosis with topiramate: a case report. Clinical Neuropharmacology. 33: 317-8. PMID 21079458 DOI: 10.1097/Wnf.0B013E3181F84A39  0.382
2010 Kirch W, Gold R, Hensel M, Fasshauer M, Pittrow D, Huscher D, Reiser M, Stangel M, Baumann U, Borte M. [Assessment of immunoglobulins in a long-term non-interventional study (SIGNS Study). Rationale, design, and methods]. Medizinische Klinik (Munich, Germany : 1983). 105: 647-51. PMID 20878302 DOI: 10.1007/S00063-010-1105-8  0.338
2010 Marx A, Hohenberger P, Hoffmann H, Pfannschmidt J, Schnabel P, Hofmann HS, Wiebe K, Schalke B, Nix W, Gold R, Willcox N, Peterson P, Ströbel P. The autoimmune regulator AIRE in thymoma biology: autoimmunity and beyond. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. 5: S266-72. PMID 20859117 DOI: 10.1097/Jto.0B013E3181F1F63F  0.301
2010 Linker RA, Lee DH, Demir S, Wiese S, Kruse N, Siglienti I, Gerhardt E, Neumann H, Sendtner M, Lühder F, Gold R. Functional role of brain-derived neurotrophic factor in neuroprotective autoimmunity: therapeutic implications in a model of multiple sclerosis. Brain : a Journal of Neurology. 133: 2248-63. PMID 20826430 DOI: 10.1093/Brain/Awq179  0.312
2010 Berger JR, Centonze D, Comi G, Confavreux C, Cutter G, Giovannoni G, Gold R, Hartung HP, Lublin F, Miravalle A, Montalban X, O'Connor P, Olsson T, Polman CH, Stuve O, et al. Considerations on discontinuing natalizumab for the treatment of multiple sclerosis. Annals of Neurology. 68: 409-11. PMID 20818795 DOI: 10.1002/Ana.22083  0.352
2010 Warnke C, Menge T, Hartung HP, Racke MK, Cravens PD, Bennett JL, Frohman EM, Greenberg BM, Zamvil SS, Gold R, Hemmer B, Kieseier BC, Stüve O. Natalizumab and progressive multifocal leukoencephalopathy: what are the causal factors and can it be avoided? Archives of Neurology. 67: 923-30. PMID 20697042 DOI: 10.1001/Archneurol.2010.161  0.404
2010 Schröder A, Lee DH, Hellwig K, Lukas C, Linker RA, Gold R. Successful management of natalizumab-associated progressive multifocal leukoencephalopathy and immune reconstitution syndrome in a patient with multiple sclerosis. Archives of Neurology. 67: 1391-4. PMID 20625069 DOI: 10.1001/Archneurol.2010.157  0.352
2010 Stüve O, Kieseier BC, Hemmer B, Hartung HP, Awad A, Frohman EM, Greenberg BM, Racke MK, Zamvil SS, Phillips JT, Gold R, Chan A, Zettl U, Milo R, Marder E, et al. Translational research in neurology and neuroscience 2010: multiple sclerosis. Archives of Neurology. 67: 1307-15. PMID 20625066 DOI: 10.1001/Archneurol.2010.158  0.374
2010 Krogias C, Schröder A, Wiendl H, Hohlfeld R, Gold R. ["Chronic cerebrospinal venous insufficiency" and multiple sclerosis: critical analysis and first observation in an unselected cohort of MS patients]. Der Nervenarzt. 81: 740-6. PMID 20386873 DOI: 10.1007/S00115-010-2972-1  0.383
2010 Blecharz KG, Haghikia A, Stasiolek M, Kruse N, Drenckhahn D, Gold R, Roewer N, Chan A, Förster CY. Glucocorticoid effects on endothelial barrier function in the murine brain endothelial cell line cEND incubated with sera from patients with multiple sclerosis. Multiple Sclerosis (Houndmills, Basingstoke, England). 16: 293-302. PMID 20203147 DOI: 10.1177/1352458509358189  0.339
2010 Hellwig K, Haghikia A, Gold R. Parenthood and immunomodulation in patients with multiple sclerosis. Journal of Neurology. 257: 580-3. PMID 19936821 DOI: 10.1007/S00415-009-5376-Z  0.341
2010 Schröder A, Linker RA, Gold R. Plasmapheresis for neuroinflammatory disorders Clinical and Experimental Neuroimmunology. 1: 95-102. DOI: 10.1111/J.1759-1961.2010.00010.X  0.366
2010 Schröder A, Meyer C, Chan A, Gold R. PE in der Eskalationstherapie der MS Nervenarzt. 81: 32-32. DOI: 10.1007/S00115-010-3149-7  0.326
2009 Linker RA, Brechlin P, Jesse S, Steinacker P, Lee DH, Asif AR, Jahn O, Tumani H, Gold R, Otto M. Proteome profiling in murine models of multiple sclerosis: identification of stage specific markers and culprits for tissue damage. Plos One. 4: e7624. PMID 19865482 DOI: 10.1371/Journal.Pone.0007624  0.349
2009 Schröder A, Linker RA, Gold R. Plasmapheresis for neurological disorders Expert Review of Neurotherapeutics. 9: 1331-1339. PMID 19769448 DOI: 10.1586/Ern.09.81  0.305
2009 Wenning W, Haghikia A, Laubenberger J, Clifford DB, Behrens PF, Chan A, Gold R. Treatment of progressive multifocal leukoencephalopathy associated with natalizumab. The New England Journal of Medicine. 361: 1075-80. PMID 19741228 DOI: 10.1056/Nejmoa0810257  0.354
2009 Moharregh-Khiabani D, Linker RA, Gold R, Stangel M. Fumaric Acid and its esters: an emerging treatment for multiple sclerosis. Current Neuropharmacology. 7: 60-64. PMID 19721818 DOI: 10.2174/157015909787602788  0.324
2009 Stegbauer J, Lee DH, Seubert S, Ellrichmann G, Manzel A, Kvakan H, Muller DN, Gaupp S, Rump LC, Gold R, Linker RA. Role of the renin-angiotensin system in autoimmune inflammation of the central nervous system. Proceedings of the National Academy of Sciences of the United States of America. 106: 14942-7. PMID 19706425 DOI: 10.1073/Pnas.0903602106  0.302
2009 Cotte S, Ahsen Nv, Kruse N, Huber B, Winkelmann A, Zettl UK, Starck M, König N, Tellez N, Dörr J, Paul F, Zipp F, Lühder F, Koepsell H, Pannek H, ... ... Gold R, et al. ABC-transporter gene-polymorphisms are potential pharmacogenetic markers for mitoxantrone response in multiple sclerosis Brain. 132: 2517-2530. PMID 19605531 DOI: 10.1093/Brain/Awp164  0.333
2009 Haghikia A, Gold R. Quinpramine: revival of old anti-inflammatory principles in multiple sclerosis? Experimental Neurology. 217: 240-1. PMID 19361499 DOI: 10.1016/J.Expneurol.2009.03.041  0.312
2009 Linker RA, Gold R, Lühder F. Function of neurotrophic factors beyond the nervous system: inflammation and autoimmune demyelination. Critical Reviews in Immunology. 29: 43-68. PMID 19348610 DOI: 10.1615/Critrevimmunol.V29.I1.20  0.318
2009 Hellwig K, Agne H, Gold R. Interferon beta, birth weight and pregnancy in multiple sclerosis Journal of Neurology. 256: 830-831. PMID 19240959 DOI: 10.1007/S00415-009-5014-9  0.319
2009 Akkad DA, Hoffjan S, Petrasch-Parwez E, Beygo J, Gold R, Epplen JT. Variation in the IL7RA and IL2RA genes in German multiple sclerosis patients. Journal of Autoimmunity. 32: 110-115. PMID 19231135 DOI: 10.1016/J.Jaut.2009.01.002  0.346
2009 Hellwig K, Schimrigk S, Beste C, Muller T, Gold R. Increase in relapse rate during assisted reproduction technique in patients with multiple sclerosis. European Neurology. 61: 65-8. PMID 19039223 DOI: 10.1159/000177937  0.337
2008 Gold R, Hohlfeld R, Toyka KV. Progress in the treatment of myasthenia gravis. Therapeutic Advances in Neurological Disorders. 1: 36-51. PMID 21180568 DOI: 10.1177/1756285608093888  0.322
2008 Stüve O, Gold R, Chan A, Mix E, Zettl U, Kieseier BC. α4-Integrin antagonism with natalizumab Journal of Neurology. 255: 58-65. PMID 19300961 DOI: 10.1007/S00415-008-6011-0  0.356
2008 Akkad DA, Kruse N, Arning L, Gold R, Epplen JT. Genomic NGFB variation and multiple sclerosis in a case control study Bmc Medical Genetics. 9: 107-107. PMID 19063739 DOI: 10.1186/1471-2350-9-107  0.351
2008 Gold R, Schneider-Gold C. Current and Future Standards in Treatment of Myasthenia Gravis Neurotherapeutics. 5: 535-541. PMID 19019304 DOI: 10.1016/J.Nurt.2008.08.011  0.335
2008 Linker RA, Lee D, Stangel M, Gold R. Fumarates for the treatment of multiple sclerosis: potential mechanisms of action and clinical studies Expert Review of Neurotherapeutics. 8: 1683-1690. PMID 18986239 DOI: 10.1586/14737175.8.11.1683  0.381
2008 Kappos L, Gold R, Miller DH, Macmanus DG, Havrdova E, Limmroth V, Polman CH, Schmierer K, Yousry TA, Yang M, Eraksoy M, Meluzinova E, Rektor I, Dawson KT, Sandrock AW, et al. Efficacy and safety of oral fumarate in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study. Lancet. 372: 1463-72. PMID 18970976 DOI: 10.1016/S0140-6736(08)61619-0  0.322
2008 Linker RA, Kieseier BC, Gold R. Identification and development of new therapeutics for multiple sclerosis Trends in Pharmacological Sciences. 29: 558-565. PMID 18804288 DOI: 10.1016/J.Tips.2008.07.012  0.383
2008 Haupts MR, Schimrigk SK, Brune N, Chan A, Ahle G, Hellwig K, König FB, Schlegel U, Brück W, Gold R. Fulminant tumefactive multiple sclerosis: Therapeutic implications of histopathology Journal of Neurology. 255: 1272-1273. PMID 18677644 DOI: 10.1007/S00415-008-0883-X  0.358
2008 Comi G, Pulizzi A, Rovaris M, Abramsky O, Arbizu T, Boiko A, Gold R, Havrdova E, Komoly S, Selmaj K, Sharrack B, Filippi M. Effect of laquinimod on MRI-monitored disease activity in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study. The Lancet. 371: 2085-2092. PMID 18572078 DOI: 10.1016/S0140-6736(08)60918-6  0.31
2008 Wüst S, van den Brandt J, Tischner D, Kleiman A, Tuckermann JP, Gold R, Lühder F, Reichardt HM. Peripheral T cells are the therapeutic targets of glucocorticoids in experimental autoimmune encephalomyelitis. Journal of Immunology (Baltimore, Md. : 1950). 180: 8434-43. PMID 18523311 DOI: 10.4049/Jimmunol.180.12.8434  0.359
2008 Linker RA, Gold R. Use of intravenous immunoglobulin and plasma exchange in neurological disease. Current Opinion in Neurology. 21: 358-365. PMID 18451723 DOI: 10.1097/Wco.0B013E3282Ff5B8F  0.338
2008 Linker RA, Weller C, Lühder F, Mohr A, Schmidt J, Knauth M, Metselaar JM, Gold R. Liposomal glucocorticosteroids in treatment of chronic autoimmune demyelination: long-term protective effects and enhanced efficacy of methylprednisolone formulations. Experimental Neurology. 211: 397-406. PMID 18394606 DOI: 10.1016/J.Expneurol.2008.02.005  0.374
2008 Gold R. Combination therapies in multiple sclerosis. Journal of Neurology. 255: 51-60. PMID 18317677 DOI: 10.1007/S00415-008-1008-2  0.335
2008 Stangel M, Moharregh-Khiabani D, Linker RA, Gold R. Fumarat in der Behandlung der Multiplen Sklerose Nervenarzt. 79: 212-217. PMID 18210050 DOI: 10.1007/S00115-007-2378-X  0.32
2008 Hellwig K, Brune N, Haghikia A, Müller T, Schimrigk S, Schwödiauer V, Gold R. Reproductive counselling, treatment and course of pregnancy in 73 German MS patients Acta Neurologica Scandinavica. 118: 24-28. PMID 18205883 DOI: 10.1111/J.1600-0404.2007.00978.X  0.34
2008 Gold R, Lühder F. Interleukin-17--extended features of a key player in multiple sclerosis. American Journal of Pathology. 172: 8-10. PMID 18063700 DOI: 10.2353/Ajpath.2008.070862  0.303
2008 Lee D, Linker RA, Paulus W, Schneider-Gold C, Chan A, Gold R. Subcutaneous immunoglobulin infusion: A new therapeutic option in chronic inflammatory demyelinating polyneuropathy Muscle & Nerve. 37: 406-409. PMID 17918749 DOI: 10.1002/Mus.20909  0.331
2008 Linker RA, Schröder AK, Gold R. Relapse Therapy in Multiple Sclerosis - The Role of Plasma Exchange European Neurological Review. 3: 104. DOI: 10.17925/Enr.2008.03.01.104  0.305
2008 Haghikia A, Fischer M, Hellwig K, Linker R, Chan A, Hohlfeld R, Gold R. Natalizumab im klinischen Alltag Nervenarzt. 79: 716-719. DOI: 10.1007/S00115-008-2558-3  0.315
2007 Gold R, Rieckmann P. Fortschritte im Verständnis von Pathogenese und Immuntherapie der Multiplen Sklerose Nervenarzt. 78: 15-26. PMID 17668159 DOI: 10.1007/S00115-007-2327-8  0.326
2007 Chan A, Gold R. Neuropsychological/-psychiatric deficits in immune-mediated neuropathies. Journal of Neurology. 254: 93-95. PMID 17503141 DOI: 10.1007/S00415-007-2023-4  0.308
2007 Gold R, Stangel M, Dalakas MC. Drug Insight: the use of intravenous immunoglobulin in neurology--therapeutic considerations and practical issues. Nature Reviews Neurology. 3: 36-44. PMID 17205073 DOI: 10.1038/Ncpneuro0376  0.347
2007 Akkad DA, Epplen JT, Gold R. „Syndrom“ multiple Sklerose Medizinische Genetik. 19: 342-345. DOI: 10.1007/S11825-007-0031-5  0.336
2007 Linker R, Lee D, Siglienti I, Gold R. Is there a role for neurotrophins in the pathology of multiple sclerosis Journal of Neurology. 254: 33-33. DOI: 10.1007/S00415-007-1007-8  0.356
2006 Reichardt HM, Gold R, Lühder F. Glucocorticoids in multiple sclerosis and experimental autoimmune encephalomyelitis. Expert Review of Neurotherapeutics. 6: 1657-1670. PMID 17144780 DOI: 10.1586/14737175.6.11.1657  0.393
2006 Gold R, Kieseier BC. Therapy of immune neuropathies with intravenous immunoglobulins. Journal of Neurology. 253: 59-63. PMID 16998755 DOI: 10.1007/S00415-006-5008-9  0.352
2006 Stasiolek M, Bayas A, Kruse N, Wieczarkowiecz A, Toyka KV, Gold R, Selmaj K. Impaired maturation and altered regulatory function of plasmacytoid dendritic cells in multiple sclerosis. Brain : a Journal of Neurology. 129: 1293-305. PMID 16513684 DOI: 10.1093/Brain/Awl043  0.374
2006 Gold R, Hohlfeld R. Multiple sclerosis therapy: new agents carry new risks Practical Neurology. 6: 248-251. DOI: 10.1136/Jnnp.2006.097873  0.403
2006 Gold R. Multiple Sklerose - zwischen Grundlagenforschung und klinischer Anwendung Psychoneuro. 32: 113-113. DOI: 10.1055/S-2006-940242  0.32
2005 Ibrahim SM, Gold R. Genomics, proteomics, metabolomics: what is in a word for multiple sclerosis? Current Opinion in Neurology. 18: 231-5. PMID 15891405 DOI: 10.1097/01.Wco.0000169738.06664.3B  0.331
2004 Gold R, Kieseier BC, Hartung H. Neue Therapieansätze bei der Multiplen Sklerose Psychoneuro. 30: 375-379. DOI: 10.1055/S-2004-831081  0.39
2003 Schmidt J, Metselaar JM, Gold R. Intravenous liposomal prednisolone downregulates in situ TNF-alpha production by T-cells in experimental autoimmune encephalomyelitis. The Journal of Histochemistry and Cytochemistry : Official Journal of the Histochemistry Society. 51: 1241-4. PMID 12923250 DOI: 10.1177/002215540305100915  0.359
2003 Chan A, Seguin R, Magnus T, Papadimitriou C, Toyka KV, Antel JP, Gold R. Phagocytosis of apoptotic inflammatory cells by microglia and its therapeutic implications: termination of CNS autoimmune inflammation and modulation by interferon-beta. Glia. 43: 231-42. PMID 12898702 DOI: 10.1002/Glia.10258  0.316
2003 Stangel M, Kiefer R, Pette M, Smolka MN, Marx P, Gold R. Side effects of intravenous immunoglobulins in neurological autoimmune disorders--a prospective study. Journal of Neurology. 250: 818-21. PMID 12883923 DOI: 10.1007/S00415-003-1085-1  0.314
2003 Schmidt J, Metselaar JM, Wauben MH, Toyka KV, Storm G, Gold R. Drug targeting by long-circulating liposomal glucocorticosteroids increases therapeutic efficacy in a model of multiple sclerosis. Brain : a Journal of Neurology. 126: 1895-904. PMID 12805101 DOI: 10.1093/Brain/Awg176  0.331
2003 Toyka KV, Gold R. The pathogenesis of CIDP: rationale for treatment with immunomodulatory agents. Neurology. 60: S2-7. PMID 12707416 DOI: 10.1212/Wnl.60.8_Suppl_3.S2  0.405
2003 Chan A, Papadimitriou C, Graf W, Toyka KV, Gold R. Effects of polyclonal immunoglobulins and other immunomodulatory agents on microglial phagocytosis of apoptotic inflammatory T-cells. Journal of Neuroimmunology. 135: 161-5. PMID 12576237 DOI: 10.1016/S0165-5728(02)00433-2  0.31
2002 Mäurer M, Toyka KV, Gold R. Immune mechanisms in acquired demyelinating neuropathies: lessons from animal models. Neuromuscular Disorders : Nmd. 12: 405-14. PMID 12062260 DOI: 10.1016/S0960-8966(01)00302-9  0.311
2002 Linker RA, Mäurer M, Gaupp S, Martini R, Holtmann B, Giess R, Rieckmann P, Lassmann H, Toyka KV, Sendtner M, Gold R. CNTF is a major protective factor in demyelinating CNS disease: a neurotrophic cytokine as modulator in neuroinflammation. Nature Medicine. 8: 620-4. PMID 12042814 DOI: 10.1038/Nm0602-620  0.341
2002 Giess R, Mäurer M, Linker R, Gold R, Warmuth-Metz M, Toyka KV, Sendtner M, Rieckmann P. Association of a null mutation in the CNTF gene with early onset of multiple sclerosis. Archives of Neurology. 59: 407-9. PMID 11890844 DOI: 10.1001/Archneur.59.3.407  0.355
2002 Ruprecht K, Warmuth-Metz M, Waespe W, Gold R. Symptomatic hyperekplexia in a patient with multiple sclerosis. Neurology. 58: 503-504. PMID 11839869 DOI: 10.1212/Wnl.58.3.503  0.32
2001 Stienekemeier M, Falk K, Rötzschke O, Weishaupt A, Schneider C, Toyka KV, Gold R, Strominger JL. Vaccination, prevention, and treatment of experimental autoimmune neuritis (EAN) by an oligomerized T cell epitope. Proceedings of the National Academy of Sciences of the United States of America. 98: 13872-7. PMID 11717443 DOI: 10.1073/Pnas.241504598  0.326
2001 Ibrahim SM, Mix E, Böttcher T, Koczan D, Gold R, Rolfs A, Thiesen HJ. Gene expression profiling of the nervous system in murine experimental autoimmune encephalomyelitis. Brain : a Journal of Neurology. 124: 1927-38. PMID 11571211 DOI: 10.1093/Brain/124.10.1927  0.305
2001 Leussink VI, Jung S, Merschdorf U, Toyka KV, Gold R. High-dose methylprednisolone therapy in multiple sclerosis induces apoptosis in peripheral blood leukocytes Archives of Neurology. 58: 91-97. PMID 11176941 DOI: 10.1001/Archneur.58.1.91  0.374
2000 Weishaupt A, Gold R, Hartung T, Gaupp S, Wendel A, Brück W, Toyka KV. Role of TNF-α in High-Dose Antigen Therapy in Experimental Autoimmune Neuritis: Inhibition of TNF-α by Neutralizing Antibodies Reduces T-Cell Apoptosis and Prevents Liver Necrosis Journal of Neuropathology and Experimental Neurology. 59: 368-376. PMID 10888366 DOI: 10.1093/Jnen/59.5.368  0.306
2000 Schmidt J, Gold R, Schönrock L, Zettl UK, Hartung H, Toyka KV. T-cell apoptosis in situ in experimental autoimmune encephalomyelitis following methylprednisolone pulse therapy Brain. 123: 1431-1441. PMID 10869055 DOI: 10.1093/Brain/123.7.1431  0.312
1999 Noseworthy JH, Gold R, Hartung H. Treatment of multiple sclerosis: recent trials and future perspectives. Current Opinion in Neurology. 12: 279-293. PMID 10499173 DOI: 10.1097/00019052-199906000-00007  0.338
1999 Stangel M, Toyka KV, Gold R. Mechanisms of high-dose intravenous immunoglobulins in demyelinating diseases. Jama Neurology. 56: 661-663. PMID 10369303 DOI: 10.1001/Archneur.56.6.661  0.365
1999 Weilbach FX, Gold R. Disease Modifying Treatments for Multiple Sclerosis Cns Drugs. 11: 133-157. DOI: 10.2165/00023210-199911020-00005  0.385
1997 Flachenecker P, Taleghani BM, Gold R, Grossmann R, Wiebecke D, Toyka KV. Treatment of severe myasthenia gravis with protein A immunoadsorption and cyclophosphamide. Transfusion Science. 19: 43-46. PMID 10178693 DOI: 10.1016/S0955-3886(97)00102-1  0.313
1997 Weishaupt A, Gold R, Gaupp S, Giegerich G, Hartung H, Toyka KV. Antigen therapy eliminates T cell inflammation by apoptosis: Effective treatment of experimental autoimmune neuritis with recombinant myelin protein P2 Proceedings of the National Academy of Sciences of the United States of America. 94: 1338-1343. PMID 9037054 DOI: 10.1073/Pnas.94.4.1338  0.327
1995 Zettl UK, Gold R, Toyka KV, Hartung H. Intravenous glucocorticosteroid treatment augments apoptosis of inflammatory T cells in experimental autoimmune neuritis (EAN) of the Lewis rat. Journal of Neuropathology and Experimental Neurology. 54: 540-547. PMID 7602327 DOI: 10.1097/00005072-199507000-00008  0.327
Show low-probability matches.